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CHAPTER- I 
INTRODUCTION 
MOBILE DRUG DELIVERY SYSTEM 
Anatomy and physiology of oral mucosa: 
The oral mucosa can be subdivided in to two general regions, the outer 
vestibule and oral cavity. Microscopically the oral mucosa consists of three main 
layers: 
A. Oral epithelium 
B. Lamina propria 
C. Sub mucosa 
A. oral epithelium: 
The epithelium of mouth consists of stratified, squamous epithelium, which 
may be either keratinized or non-keratinized, keratinized epithelium is 
dehydrated, mechanically in areas such as the soft palate, the floor of mouth, the 
lips and the cheeks tough and chemically resistant. It is found in oral cavity such 
as mucosa of gingival and hard palate.Nonkeratinized epithelium is relatively 
flexible and is found. The epithelium of the oral cavity is supported by the 
basement membrane. The 
membrane separates the epithelium 
from the underlying connective 
tissue layer. This process is 
represented in four morphological 
layers. 
CHAPTER – I                                                                      INTRODUCTION 
DEPT.OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                Page 2 
 Basal layer 
 Prickle cell layer 
 Intermediate layer 
 Superficial layer 
B. lamina propria: 
The lamina propria contents a sheet of connective tissue containing 
collagen elastic fiber and cellular components in hydrated ground substance.  It is 
also consists of blood capillaries and nerve fibers which serves the mucosa. The 
blood vessels in the laminapropria are mainly engaged in the delivery of drug 
moieties in systemic circulation. 
C. Sub mucosa: 
A sub mucosa may or may not be present deep to the dense layer of the 
lamina propria; depending on the region of the oral cavity. The sub mucosa 
usually contains loose connective tissue and also adipose connective tissue or 
salivary glands and also overlying bone or muscle within the oral cavity. Saliva is 
a hypotonic, watery secretion containing variable amount of mucus, enzyme, 
antibodies and inorganic ions. The surface of mucus membrane is constantly 
washed by a stream of about 0.5 to 2L of saliva daily produce in the salivary 
gland the chief secretion is supplied by three pairs of glands i.e. the parotid, the 
sub maxillary and the sublingual glands. 
NOVEL APPROACHES- BUCCAL DRUG DELIVERY SYSTEMS: 
Buccal drug delivery is one of the novel drug delivery systems. It localized 
the delivery to tissues of the oral cavity for the treatment of bacterial and fungal 
infection as well as periodontal disease. Buccal drug delivery also a safer mode 
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of drug delivery system and can be able to remove in case of toxicity and adverse 
effect. Buccal mucosa has an excellent accessibility, which leads to direct access 
to systemic circulation through the internal jugular vein bypasses the drug from 
hepatic first pass metabolism. 
The administration of drug through buccal route provides a direct entry of 
drug molecule into the systemic circulation via avoiding the first pass metabolism. 
it is possible bypasses of first pass effect and avoidance of pre-systemic 
elimination within the gastrointestinal tract. Buccal route is preferred the drugs 
having poor bioavailability because of high first pass metabolism. Chewing gums 
much more readily tolerated by the patient than tablets. Moreover, the chewing 
gums are able to protect the buccal surface, thus reducing infections and treating 
oral diseases more effectively. 
Oral mucosa: 
The total area of the oral cavity is 100cm2 .one third is the buccal surface, 
which is lined with an epithelium of about 0.5mm thickness. The main role of oral 
mucosa is protection of tissue underlying. Lipid based permeability barriers in 
epithelium layer protect the tissues from fluid loss and also from the attack of 
harmful environmental agents like microbial toxins, antigens, carcinogens, 
enzymes etc. Oral epithelium proliferation time is 5-6 days. Oral cavity is that 
area of mouth delineated by the lips, cheeks, hard palate, soft palate and floor of 
mouth. The oral cavity consists of two regions. outer oral vestibule which is 
bounded by cheeks, lips, teeth and gingival(gums).oral cavity proper which 
extends from teeth and gums back to the faucets(which lead to pharynx)with the 
roof comprising the hard and soft palate. The tongue projects from the floor of the 
cavity. 
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FUNCTIONS OF ORAL CAVITY: 
 It helps in chewing, mastication and mixing of food stuff. 
 It is helps to lubricate the food material and bolus. 
 To identify the ingested material by taste buds of tongue. 
 To initiate the carbohydrate and fat metabolism. 
 As a portal for intake of food material and water. 
Methods of increase drug delivery via buccal route: 
1. Permeation Enhancers: 
The epithelium that lines the buccal mucosa is a very effective barrier to 
the absorption of drugs. Sub-stances that facilitate the permeation through buccal 
mucosa are referred as the absorption enhancers. As most of the absorption 
enhancers were originally designed for increase the absorption of drug and 
improved efficacy and reduced toxicity. However, the selection of enhancer and 
its effectively depends on the physicochemical properties of the drug, site of 
administration, nature of the vehicle and other excipients. In some cases usage 
of enhancers in combination has shown synergistic effect than the individual 
enhancers. The efficacy of enhancer in one site is not some in the other site 
because of differences in cellular morphology, membrane thickness, enzymatic 
activity, lipid composition and potential protein interactions are structural and 
functional properties. The most common absorption enhancers are fatty acids, 
bile salts and surfactants such as sodium dodecyl sulfate. Solution/gels of 
chitosan were also found to promote the transport of mannitol and fluorescent-
labeled dextrin’s across a tissue culture model of the buccal epithelium while 
CHAPTER – I                                                                      INTRODUCTION 
DEPT.OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                Page 5 
Glyceryl monooleates were reported to enhance peptide absorption by a co-
transport mechanism. 
IDEAL REQUIREMENTS FOR DRUG PROFILE: 
1. The drug should not have any type of disagreeable taste, this can affect 
patient compliance. 
2. The particle size of the drug should be kept below approximately 100 cm 
to avoid unpleasant gritty feeling during chewing. 
PHYSICO CHEMICAL PROPERTIES OF DRUG: 
 High salivary solubility. 
 pH independent solubility. 
 Tasteless. 
PATIENT RELATED FACTORS: 
 Non toxic to oromucosa and salivary ducts. 
 Non carcinogenic. 
 Should not cause tooth decay and oromucosa staining should not affect 
salivary flow rate. 
MECHANISM:                                                                                                    
Mechanisms by which penetration enhancers are thought to improve 
mucosal absorption are as follow. 
 Changing rheology  mucus: 
Mucus forms viscoelastic layer of varying thickness that affects drug 
absorption. Future, saliva covering the mucus layers also hinders the absorption. 
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Some permeation enhancers’ act by reducing the viscosity of the mucus and 
saliva overcomes this barrier. 
 Increasing the fluidity of lipid bilayer membrane: 
The most accepted mechanism of drug absorption through buccal mucosa 
is intracellular route. Some enhancers disturb the intracellular lipid packing by 
interaction with either lipid packing by a interaction with either lipid or protein 
components. 
 Acting on the components at tight junctions: 
Some enhancers act as desmosomes, a major component at the tight 
junctions there by increases drug absorption. 
 By overcoming the enzymatic barrier: 
These act by inhibiting the various peptidases and proteases present 
within buccal mucosa, thereby overcoming the enzymatic barrier. In addition, 
changes in membrane fluidity also alter the enzymatic activity indirectly. 
 Increasing the thermodynamic activity of drugs: 
Some enhancers increase the solubility of drug there by alters the partition 
coefficient. This leads to in-creased thermodynamic activity resulting better 
absorption. Surfactants such as anionic, cationic, nonionic and bile salts 
increases permeability of drugs by perturbation of interfering with the calcium 
ions, fatty acids by increasing fluidity of phospholipids and positively charged 
polymers by ionic interaction with negative charge on the mucosal surface. List of 
some permeation enhancer are listed in table. 
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Table1: Permeation Enhancers for Buccal Delivery:   
S.no Permeation Enhancers   s.no     Permeation Enhancers 
1. 2, 3-Lauryl ether    12.    Phosphatidylcholine 
2. Aprotinin     13.    Polyoxyethylene 
3. Azone      14.    Polysorbate 80 
4. Benzalkonium chloride   15.    Polyoxyethylene 
5. Cetylpyridinium    16.    Phosphatidylcholine 
6. cetyltrimethyl ammonium bromide 17.        Sodium EDTA     
7. Cyclodextrin     18.   Sodium glycocholate 
8. Dextran sulfate    19.       Sodiumglycodeoxcholate 
9. Glycol      20.      Sodium lauryl sulfate   
10. Lauric acid     21. Sodium salicylate 
11. Lauric acid/Propylene   22. Sodium taurocholate 
 
2. Prodrug: 
 Nalbuphine and naloxone bitter drugs when administered to dogs via 
buccal mucosa causes excess salivation and swallowing. As a result, the drug 
exhibited low bioavailability. Administration of nalbuphine and naloxone in prod 
rug form caused no adverse effects, with bioavailability ranging from 35 to 50% 
showing marked improvement over the oral bioavailability of these compounds. 
3. pH: 
 The in vitro permeability of acyclovir was found to be pH dependent with an 
increase in flux and permeability coefficient at both pH extremes (pH 3.3 and 
8.8),as compared to the mid-range values (pH 4.1,5.8,and 7.0). 
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ABSORPTION OF DRUG ACROSS THE ORAL MUCOSA: 
 The oral cavity is point of entry for oral drug formulations but their contact 
with the oral mucosa is brief. So in to order to take advantages of these 
properties or to treat the mucosa locally, this delivery system have been designed 
to prolong residence in this area. The total surface area available for drug 
absorption is quite limited being only approximately 100cm2. The oral cavity is 
rich in blood vessels and lymphatic, so rapid onset of action and high blood levels 
obtained quickly. 
 In order to absorb orally, the drug must be dissolve in saliva. Extremely 
hydrophobic materials will not dissolve well and are likely to be swallowed intact 
unless a specialized delivery system is used to prevent them to mucosa. 
THEORY OF DRUG TRANSPORT: 
Due to chewing process, most of the medications contained within the 
drug product are released into the saliva and are either absorbed through buccal 
mucosa or swallowed or absorbed through GIT as depicted in Figure 1. 
 
 
 
 
 
 
 
FIGURE 1: SCHEMATIC SEQUENCE OF MECHANISM OF DRUG RELEASE FROM MCG. 
Medicated Chewing Gum Chewing 
Drug release Mixed with saliva 
Drug Absorption 
Through Buccal Mucosa 
Through GIT (After swallowing) 
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 Major pathways of drug transport across buccal mucosa follow simple 
fickian diffusion. Passive diffusion occurs in accordance without the pH partition 
theory, some carrier mediated transport also observed. Equation for drug flux is: 
J=DKp/∆Ce 
Where J= Drug, D=Diffusivity, Kp = Partition coefficient and ∆ Ce=Conc. 
Gradient. 
Mechanism of drug Transport: 
 Major pathways of drug transport across the buccal mucosa follow simple 
fickian diffusion. Passive diffusion occurs in accordance without the pH partition 
theory. Some carrier mediated transport also observed. Equation for drug flux is: 
J = DKp/∆Ce 
Where, 
J=Drug fiux 
D=Diffusivity 
Kp=partition coefficient 
∆Ce=Concentration gradient 
h=diffusional path length 
According to the equation, the flux may be increased by: 
 Decreasing the diffusion   resistance of the membrane by making it more 
fluid, 
 Increasing the solubility of the drug in the saliva immediately adjacent  to 
the epithelium Enhancing the lipophilicity through pro-drug modification. 
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 Because of the barrier properties of the tight buccal mucosa, the rate 
limiting step is the movement of the drug molecules across the epithelium. 
DRUGS REPORTED TO BE BEST SUITABLE IN CHEWING GUM 
FORMULATIONS: 
List of commercially available medicated chewing gums: 
S. 
No 
Trade Mark active ingredient Indication 
1. Aspergum Aspirin pain relief 
2. Orbit white tricalcium  phosphate dental   hygiene 
3. Happy dent white sodium chloride anti caries agent 
4. Travel gum dimenhydrinate motion sickness 
5. Super pep dimenhydrinate motion sickness 
6. Nicorette Nicotine smoking cessation 
7. Nicotinelle Nicotine smoking cessation 
8. Hex it Chlorhexidine Antibacterial 
9. Stay alert Caffeine cns stimulant 
10. Chooz calcium carbonate Antacid 
11. Endekay vitamin c Supplement 
12. Go gum Guarana Alertness 
13. Brain DHA and CCE Enhanced brain 
activity 
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CHAPTER-II 
CHEWING GUM - A REVIEW 
 Chewing gums are mobile drug delivery system. It is a potentially useful 
means of administrating drugs either locally or systemically via the oral 
cavity. 
 The medicated chewing gum has through the years gained increasing 
acceptance as a drug delivery system.MCG is a solid single dose 
preparations with a base consisting mainly of gums with are indented to be 
chewed but not  swallowed, providing a slow steady release of the 
medicine contained. 
 It’s a novel drug delivery system containing masticator gum base with 
pharmacologically active ingredient and indented to use for local treatment 
of mouth diseases or systemic absorption through oral mucosa. 
 The buccal route of drug administration also has important advantages of 
direct access to the general circulation and overcomes the first pass 
hepatic metabolism. As chewing gums are taken orally and oral route of 
drug delivery is the most preferred route amongst the patient and clinicians 
due to various advantages it offers, in recent years chewing gums are 
considered to be friendly oral mucosal drug delivery system. 
 Children in particular may consider chewing gum as a more preferred 
method of drug administration compared with the oral liquids and tablets. 
The use of MCG is feasible in local treatment of disease of oral cavity as 
well as treatment of systemic conditions. 
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 Chewing gum is considered a valid drug delivery system that releases the 
active ingredient by chewing. MCG has been proven as a great delivery 
vehicle for nutrients and drugs. 
 Chewing gum is mixture of natural or synthetic gums and resins 
sweetened with sugar, corn syrup, artificial sweeteners and may also 
include coloring agents and flavors bulking agents, softening agents, 
antioxidants, and glidants. MCG are prepared by different methods like 
direct compression method, conventional, traditional method, cooling and 
grinding method. 
 A medicated chewing gum is intended to be chewed for a certain period of 
time, required to deliver the dose, after which the remaining mass is 
discarded. During the chewing process the drug contained in the gum 
product is released from the mass into saliva and could be absorbed 
through the oral mucosa (or) swallowed reaching stomach for gastro-
intestinal absorption. 
 The first commercial chewing gum “State of Maine pure spruce gum” was 
marketed in 1948 in the USA. The first patent was field in 1869. The gum 
was intended as dentifrices but it has never been marketed. The first 
medicated chewing gum “As per gum” was launched in 1928. This 
chewing gum is still available and contains acetyl salicylic acid. Author 
commercially available medicated chewing gum is dimenhydrinate 
containing chewing gum for motion sickness. 
 However, chewing gum did not gain acceptance as a reliable drug delivery 
system until 1978, when nicotine chewing gum became available. 
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 Moreover, it also benefits from advantages inherout to chewing gum such 
as oral care, stress relief improved focus and concentration and weight 
management. 
 A medicated chewing gum is intended to be chewed for a certain period of 
time, required to deliver the dose, after which the remaining mass is 
discarded.   
 This drug delivery system provides benefits such as pleasant taste fast 
onset of action and high bio availability, higher patient compliance, ready 
for use and fewer side effects over tablets (or) liquid formulations. 
 The release of a drug from chewing gum is dependent upon its water 
solubility. Water soluble substances are released rapidly and completely 
from chewing gum and methods are available which retard their release 
from chewing gum to provide an extended release profile. 
 Few drugs are suitable candidates for incorporation into chewing gum 
formulations for the intention of their systemic delivery. 
 Intra oral dosage forms deliver the drug to the target sites for local or 
systemic drug delivery in the oral cavity include the following. (Abilash 
mund et al.,2015) 
MCG is a novel drug delivery system containing masticatory gum base 
with pharmacologically active buccal ,sublingual, peritoneal, tongue (lingual) and 
gum (gingival).The various types of intra oral dosage forms include liquid 
(solution, sprays, syrups, injection etc).  semi solids (ointment, pastes etc) and 
semisolid dosage forms (quick – dissolve and slow-dissolve tablets, sublingual 
tablets, lozenges, films, filaments, gums, patches, micro particles, drug delivery 
devices. intra oral drug delivery overcomes hepatic first pass metabolism and 
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promotes rapid systemic delivery with improved bioavailability with selected drugs 
having the required physiochemical and biopharmaceutical characteristics. 
DEFINITION: 
A medicated chewing gum is solid single dose preparation that is intended 
to be chewed for a certain period of time deliver the drug one active 
pharmaceutical ingredient and indented to use for local treatment of mouth 
diseases or systemic absorption through oral mucosa. 
The drug product is indented to be chewed in the oral cavity for a specific 
period of time after which the insoluble gum base is discarded. 
BENEFITS OF CHEWING GUM: 
 ADVANTAGES: 
         Medicated chewing gums offer a range of advantages. 
 Chewing gum can be used without water at any time and everywhere. 
 As the incorporated therapeutic agents are protected from oxygen light 
and water product stability is good. 
 Compatible for patients having difficult in swallowing. 
 Excellent for acute medication. 
 Counteracts dry mouth prevents candidiasis, and caries. 
 Fast and rapid onset of action. 
 High bioavailability. 
 Pleasant taste. 
 By passes first pass metabolism and thus increases the bioavailability of 
drugs. 
 Ready for use. 
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 Fewer side effects. 
 Local effect. 
 Improved focus and concentration stress relief. 
 Duration of action is increased. 
 Stimulates flow of saliva in the mouth. 
 Gum does not react the stomach hence G.I.T suffers less from the effects 
of excipients. 
 Helps whiter teeth by reducing and preventing stains. 
DISADVANTAGES: 
 Sorbitol present in MCG formulation may causes side effects like diarrhea, 
flatulence. 
 Chewing gum has been shown to adhere to difficult degrees to enamel 
dentures and fillers. 
 Prolonged chewing of gum may result in pan in facial muscles and ears in 
characters. 
CHARACTERISTIC FEATURES OF CHEWING GUM: 
 Chewing gum is a soft cohesive substance designed to the chewed 
without designed being swallowed. 
 Modern chewing gum is composed of gum base , sweeteners, softeners, 
plasticizers flavors, colors and typically a hard or powdered polyol coating. 
 Its texture is reminiscent of rubber because of the physical chemical 
properties of its polymer plasticizer and resin components which 
contributes to its elastic plastic, sticky, chewy characteristics. 
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POLYMERS USED IN CHEWING GUM PREPARATION: 
There are various polymers co polymers cross linkers are used in the 
preparation of chewing gum. 
Polymers: 
Hyper linked polystyrenes cyclodextrins and its derivatives like 
cyclodextirns, methyl B cyclodextrins, hydroxypropyl β- cyclodextrins, poly 
isoprene, poly butadiene. 
Co-polymers: 
Polyvinyl alcohol, poly vinyl acetate, styrene –butadiene copolymers, vinyl 
acetate–vinyl laureate copolymers, copolymers of lacticacid, polyhydroxy 
alkonates, plasticized ethyl cellulose, polyvinyl acetate phthalate and 
combinations there of. 
Cross linkers: 
Cross linked poly vinyl pyrrolidone, poly methyl methacrylate. 
BASIC COMPONENTS OF MEDICATED CHEWING GUMS: 
I. Active pharmaceutical ingredient (API): 
The active pharmaceutical ingredients should be comply the following 
criteria. The drug should not have any type of disagreeable taste, this can affect 
patient compliance. 
The particle size of the drug should be kept below approximately 100µm 
avoid unpleasant gritty feeling during chewing. 
Physicochemical properties of drug such as high salivary and pH 
independent solubility. 
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Patient related factors such as nontoxic to oromucosa and salivary 
ducts, non carcinogenic should not cause tooth decay and oromucosa 
staining should not affect salivary flow rate. 
II. Gum base: 
It is an insert and insoluble nonnutritive product used as a support for the 
edible and soluble of the chewing gum (sugar, glucose, poly oils and flavors)other 
raw materials are generally grouped in the following classes: 
1. Elastomers: 
It provides elasticity, gummy texture and cohesion to the chewing gum. 
Natural elastomer natural rubber like latex or natural gums such as jelutong, 
lechicaspi,perillo, and chicle. Synthetic elastomers like polyethylene acetate, 
polyisobutylene and buty-1- rubber are used. 
2. Plasticizers: 
These are used to regulate cohesiveness of product. These are again 
divided into natural and synthetic natural plasticizers include natural rosin esters 
like glycerol esters or partially hydrogenated rosin, glycerol esters of polymerized 
esters, glycerol esters of partially dimerized rosin & pentaerythritol esters of resin. 
Synthetic Plasticizers include terpene Resins derived from α-pinene and or d-
limonene. 
3. Resins: 
They serve two functions. One, as mastication substance and other as 
binding agent between elastomers and fillers, they contribute to the balance 
between the properties of elasticity and plasticity. Glycerol esters from pine resins 
are examples of natural resins. Synthetic resin polyvinyl acetate can be used. It 
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reduces the tendency of the gum to adhere to the teeth (detackifier) and to be 
divided into pieces during chewing. It has only a slight taste, its stability is good 
and it is available in range of different molecular weights. 
4. Emulsifiers and Fats: 
These are used to soften the mixture and give the required chewing 
consistency and mouth feel. Emulsifiers promote the uptake of saliva into the 
chewing gum during mastication. Monoglycerides, diglycerides and partly 
hardened vegetable and animal fat are examples. Softeners include glycerin, 
Lecithin, Tallow, Mono/ di/ tri-Glycerides, palmitic acid. 
5. Fillers or Textures: 
They provide the right texture, improve reasonable size of the gum lump 
with low dose drug for the gum base. Commonly used fillers are magnesium and 
calcium carbonate, Ground Limestone, Magnesium and Aluminum silicate, Clay, 
Alumina, Talc, Titanium Oxide &  Mono /di /tri Calcium Phosphate. Antioxidants: 
They may be added to protect the gum base and flavors from Oxidation. Ascorbic 
acid, tocopherol, butylhdroxytoluene have been used. 
6. Sweeteners: 
a. Water-soluble sweetening agents: 
Xylose, ribulose, glucose, mannose, galactose, fructose, sucrose, maltose, 
and invert sugar partially hydrolyzed starch, dihyrochalcones, monellin, 
steviosides, glycyrrhizin, and sugar alcohols such as sorbitol, mannitol, and 
hydrogenated starch hydrolsates. 
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b. Water-soluble, artificial sweeteners: 
Soluble saccharin salts, i.e. sodium or calcium saccharin salts, cyclamate 
salts. 
c. Dipeptide based sweeteners: 
L-aspartic acid derived sweeteners such as Aspartame, Alitame, methyl 
esters of L-aspartyl-L phyenylglycerine and L-aspartyl-L 2,5-
dihydrophenylglycine, L aspartyl 2, and 5-dihydro-L phenylalanine-L(1-
cyclohexen) alanine. 
d. protein based sweeteners: 
Such as thaumaoccousdanielli (Thaumatin I and II) In general an effective 
amount of sweetener is utilized to provide the level of sweetness desired, and 
this amount will vary with the sweetener selected and are present in amounts 
from 0.0025% to 90% by weight of the gum composition. 
7. flavoring agents: 
A variety of flavoring agents are used to improve flavor in chewing gum 
includes essential oils, such as citrus oil, fruit essences peppermint oil, spearmint 
oil, clove oil and oil of wintergreen. Artificial flavoring agents can also be used. 
8. Anti –caking agent: 
An anti-caking agent such as precipitated silicon dioxide can be mixed with 
chewing gum composition and solid carbon dioxide prior to grinding. This helps to 
prevent agglomeration of the subsequently ground chewing gum particles. 
9.Antioxidants: 
An anti-oxidant such as butylated hydroxytoluene , butylatedhydroxy 
anisole, propyl gallate and mixtures thereof, may be included as antioxidants. 
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10. Grinding agents: 
To prevent the gum from sticking to the grinding apparatus 2-8% w/w of 
grinding aid such as alkaline metal phosphate, an alkaline earth metal phosphate 
or maltodextrin can be incorporated. However practical use of these substances 
is limited because these substances are highly alkaline and hence would be 
incompatible with acidic ionizable therapeutic agents. They also tend to remain in 
the composition and final chewing gum tablet and thus may be problematic for 
therapeutic and safety point of view. 
Chewing gum types: 
Chewing gum comes in a variety of flavors, shapes and sizes. There is no 
standard type of gum, but mostly is a small stick or wad of gum. Chewing gum is 
basically made by combining a water-insoluble phase with a water-soluble phase 
of sweeteners, flavoring and food coloring. 
Today’s basic types of chewing gums are 
 Bubble gum: 
          Bubble gum has property of blowing bubbles because film -forming 
characteristics. 
 Sugar-free gum: 
Instead of sugar, sugar-free gum has artificial sweeteners to provide the 
taste . 
 Center-filled gum: 
Center-filled gum in his center has a soft mass, Usually filled with some 
tasty liquid. 
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 Dragee gum: 
Dragee  gum has the most popular format for chewing gum, Dragee gum 
is a pillow –shaped coated pellet, often packed in blister packs. 
 Medicated gum: 
Medicated gum is a chewing gum with a purpose to introduce medicated 
substances into blood stream faster than pills. Based on the shapes, they 
are named as: 
 Stick gum: 
Stick gum is a thin, flat, slab of gum usually in rectangular shape. 
 Ball gum: 
The gum has shape like ball. It is one of the most popular chewing gums. 
 Ribbon gum: 
Ribbon gum is like the stick gum, it is longer, coiled up in a cylindrical 
container, and the consumer tears off a piece of the size he wants. 
 Wrap gum: 
Wrap gum and cut gum is usually in the form of a chunk, cube or 
cylindrical shape, depending of the machine that wraps it. 
 Tab gum: 
Tab gum is shorter than stick gum and also thicker. 
 Tube gum: 
Tube gum or spaghetti gum comes in a tube and gum inside tube is a very 
soft bubble gum. 
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MANUFACTURING PROCESSES: 
             Different methods can be employed for the manufacturing of MCGs; 
however, these can be broadly classified into three main classes namely: 
1. Conventional/ Fusion method 
2. Cooling, grinding and tab letting method 
3. Direct compression method 
1. Conventional / Fusion Method: 
 Components of gum base are softened or melted and placed in a 
planetary mixer to which sweeteners, syrups, active ingredients and other 
excipients are added at a definite time. The gum is then sent through a series of 
rollers that forms into a thin, flat ribbon. During this process, a light coating of 
finely powdered sugar or sugar substitutes is added to keep the gum away from 
sticking and to enhance the flavor. In a carefully controlled room, the gum is 
cooled for up to 2 days. This allows the gum to set properly. Finally the gum is cut 
to the desired size and cooled at a carefully controlled temperature and humidity 
as depicted in Figure 2 
. 
 
 
 
 
 
Gum Base Drying/Purification Blending with 
other additives 
Molding/Rolling Melting with 
continuous stirring 
CHAPTER-II                                                               CHEWING GUM- A REVIEW 
DEPT.OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                Page 23 
Limitations: 
 Elevated temperature used in melting restricts the use of this method for 
thermo labile drugs. 
 Melting and mixing of highly viscous gum mass controlling of 
accuracy and uniformity of drug dose difficult. 
 Lack of precise form, shape or weight of dosage form.  
 Technology not so easily adaptable to incorporate the stringent 
manufacturing conditions required for production of pharmaceutical 
products.  
 Such a chewing gum composition is difficult to form into chewing 
gum tablets because of their moisture content (2-8%). If attempted 
to grind and tablet such a composition would jam the grinding 
machine stick to blades, screens adhere to punches and would be 
difficult to compress. 
Cooling, Grinding and Tableting Method: 
                 This method has been developed with an attempt to lower the 
moisture content and alleviate the problems mentioned in conventional method. 
The MCG base is cooled to a temperature at which the composition is sufficiently 
brittle and would remain brittle during the subsequent grinding step without 
adhesion to the grinding apparatus. The temperature required for cooling is 
determined in part by the composition of the MCG and is easily determined 
empirically by observing the properties of the cooled chewing gum composition. 
Generally the temperature of the refrigerated mixture is around  -15ºC or lower. 
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Amongst  the various coolants like liquid  nitrogen, hydrocarbon slush use of solid 
carbon dioxide is preferred as it can give temperature as low as -78.5ºC, it 
sublimes readily on warming the mixture, is not absorbed by the chewing gum 
composition, does not interact adversely with the processing apparatus and does 
not leave behind any residue which may be undesirable or potentially hazardous. 
The refrigerated composition is then crushed or ground to obtain minute 
fragments of finally ground pieces of the composition. Alternatively, the steps of 
cooling the chewing gum composition can be combined into a single step. As an 
example, cooling the grinding apparatus itself which can be done by contacting  
the grinding apparatus with a coolant or by placing the grinding apparatus in a 
cooling jacket of liquid nitrogen or other chilled liquid, for more efficient cooling, 
the chewing gum composition can be pre cooled prior to cooling to the 
refrigeration temperature. Sometimes a mixture of chewing gum composition, 
solid carbon dioxide and precipitated silica  is ground in a mill grinder in the first 
step. Additional solid carbon dioxide and silica are added to the ground 
composition, and the composition is further ground in the second step. This two-
step grinding process advantageously keeps the chewing gum composition at a 
very low temperature. The presence of solid carbon dioxide also serves to 
enhance the efficiency of the grinding process. The same process can be made 
multiple by adding incorporating additional carbon dioxide and/or precipitated 
silica at each step. Certain additives can be added to the chewing gum 
composition to facilitate cooling, grinding and to achieve desired properties of 
chewing gum. These include use of anti-caking agent and grinding agent 25. Once 
the coolant  has been removed from the powder, the powder can be mixed with 
other ingredients such as binders, lubricants, coating agents, and sweeteners 
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etc, all of which are compatible with the components of the chewing gum base in 
a suitable blender such as sigma mill or a high shear  mixer. Alternatively a 
Fluidized Bed Processor(FBP) can be used. The use of FBP is advantageous as 
it partially rebuilds the power into granules, as well as coats the powder particles 
or granules so obtained can be mixed with anti –adherents like talc. The mixture 
can be blended in an octagonal blender, screened & staged for compression. 
Limitation: 
                It requires equipment other than conventional table ting equipment and 
requires careful monitoring of humidity during the table ting process. 
3. Direct compression Method: 
              The manufacturing process can be accelerated if a directly compressible 
chewing gum excipient is available. The limitation of melting & freezing can be 
overcome by the use of these.SPI pharma has developed a compatible system 
known as pharmagum is a mixture of polyols and of sugar with gum base, 
Pharmagum  S consists primarily of gum base and sorbitol. Pharmagum M 
contains gum base, Mannitol and Isomalt. These are free following powders, 
which are directly compressible. It is manufactured under CGMP conditions and 
complies with food chemicals Codex specifications as well as with FDA, so they 
can be considered as “Generally regarded as safe” (GRAS) 27. 
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Figure 3: Schematic sequence of Cooling, Grinding and Tableting Method 
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 Formulation Aspects: 
 Cyclodextrin complexation or solubilization technique increases aqueous 
solubility of drugs that are poorly water soluble. 
 Increased amount of softeners and emulsifiers in gum base fasten release 
whereas hard gum may retard. 
 A solid system of lipophilic active ingredients bound to the cat ion 
exchange resin permits a sustained drug delivery system. 
 Microencapsulation or agglomerations are the methods to modify and 
control the release of active ingredient. 
Factors Affecting Release of Active Ingredient: 
Several factors have been shown to affect release of drugs from chewing 
gum. The major determinants include the chewing time, chewing rate, aqueous 
solubility of the drugs, and composition of the chewing gum. 
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1. Contact Time and rate: 
The local or systemic effect is dependent on time of contact of MCG in oral 
cavity; a survey was made to determine the length of chewing time. The mean 
chewing time per piece of gum was 30 to 35 min. the rate at which a subject 
chews gum also affects the amount of drug released. The average chewing rate 
is about 60 chews every minute. 
2. Inter individual variability: 
The chewing frequency and chewing intensity which affect the drug 
release from MCG may vary from person. In-vitro study prescribed by European 
Pharmacopeia suggest 60 cycles per minute chewing rate for proper release of 
active ingredient. 
3. Solubility of the drug: 
The saliva soluble ingredients will be immediately released within few 
minutes whereas lipid soluble drugs are released first into the gum base and 
then released slowly. Release of water soluble drug (aqueous solubility greater 
than 1:10) is, in general, about 75% or more during 5 min. of chewing and 90% 
or more during 15 min. of chewing at rate of 60 chews per minute. Drugs with 
aqueous solubility  between 1:10 and 1:300 demonstrate up to 60% release 
during 10 minutes of chewing and between 50 to 90% when the gum is chewed 
for 15 min the release of the drug, which is only slightly water-soluble, can only 
be excepted to be small (less than 5%)even if the gum is chewed for 30 min. 
 
 
 
CHAPTER-II                                                               CHEWING GUM- A REVIEW 
DEPT.OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                Page 28 
4. Formulation factors: 
The influence of gum base mass on drug release is depends upon 
changing the hydrophilic/lipophilic balance of the chewing gum formulation. The 
simplest way of achieving this is to increase or decrease the amount of gum 
base. An increase in the gum base will make the formulation more lipophilic and 
thus reduce the release rate of a given active substance. In principle, it is 
possible to manufacture products with a very low gum base content in practice a 
portion of chewing gum containing less than 20% gum base but will have inferior 
chewing properties and may not be considered a viable formulation. Instead of 
changing the gum base content, it is far more effective to change the release 
properties by adding solubilizers to the formulation. This method enables release 
from the chewing gum of even highly insoluble substances, e.g. Nystatine. 
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CHAPTER-III 
LITERATURE REVIEW 
 Abin L Alex et al, [2017] developed and evaluations of chewing gum of 
antiemetic drug Domperidone. Aim of present of chewing gum of 
domperidone was formulated to accelerate the onset of action and to 
improve the bioavailability so as to get quick relief from nausea and 
vomiting with greater patient compliance. In this study, ten formulations of 
domperidone were formulated as a chewing gum & best formulation was 
film coated. In each formulation, drug concentration remains the same the 
excipients concentration was varied. The prepared powder blend was 
evaluated for it’s preformulation characteristics viz, true density, bulk 
density, compressibility index, angle of repose, Hardness, Friability, weight 
Variation, thickness, drug contet, Sickness,& in vitro dissolution analysis. 
Optimized formulation f10 prepared by solid dispersion showed a drug 
release of 97.68% and 99.9% clearly complies f10 was film coated using 
HPMC.  
 Kop pula Rajitha et, al, [2016], Formulation and evaluation of medicated 
chewing gum of chlorpheniramine maleate. The aim of the work was to 
achieve better patient compliance and improved the drug release. The 
medicated chewing gums are prepared by melting method. In this method 
different concentrations of gum base and plasticizers like glycerol and 
castor oil. The prepared chewing gums are evaluated for different 
parameters like appearance, stickiness, weight variation, drug content, 
hardness, thickness, in vitro drug release. Invitro release profiles of 
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medicated chewing gum during 30 minutes studies were found to have 
very good release efficacy. It was observed that as the concentration of 
synthetic gum base increases drug releases was decreases. 
 Rahul B.Shete* et al (2015) formulated medicated chewing gum to 
prevent motion sickness. Using natural gum base for faster onset of 
action, easy administration, anywhere & any time, without access to water. 
Natural gum base prolamin extracted from wheat, showed good chewing 
capacity, elasticity, high water retention capacity, and three-level factorial 
design. Results revealed that medicated chewing gum containing 80 mg of 
calcium carbonate & 500 mg of gum base showed elasticity and more than 
90% drug release with 16 minutes. Thus, this study suggested that both 
good elasticity and chew ability and availability grain can act as a potential 
gum base for medicated chewing gum. 
 Several ingredients are now incorporated in medicated chewing gum, 
eg.fluoride for prophylaxis of dental carries. This  review article is nicely 
discussed advantages, disadvantages, formulation, manufacturing 
process, limitation of manufacturing process, factors affecting release of 
active substance, quality control tests for chewing gum, significance, 
stability study and future trends in chewing gum drug delivery system.  
 Jyoti Ran male *et, al (2015) developed the formulation development and 
evaluation of Amoxicillin based medicated chewing gum for its 
antibacterial activity. The aim of present study was to design and 
characterize medicated chewing gum for the treatment of bacterial 
infection using Amoxicillin trihydrate as model drug. The chewing gums 
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were prepared using Health in gum grade 01(HiG -01) as a directly 
compressible gum base developed by cafosa (S.A.U.) Spain. The effect of 
concentration of (Base) gum base, (release modifier) Aerosil, and 
(antiadherant) talc was studies. After oral administration it’s rapidly 
abosorbed. Maximum peak plasma concentration is reached after 
approximately 1hr this model drug is selected for the study in order to 
overcome the hepatic first pass effect and there by possible. Reduction in 
the dose. The drug is tasteless so there bioavailability, less side effects 
and has short duration of action of about 1.20hr these factors make 
Amoxicillin trihydrate is suitable Amoxicillin for formulation of medicated 
chewing gum used to treat bacterial infection.  
 Padmini Iriventi et, al (2015) Developed the formulation and evaluation of 
domperidone chewing gum for anti emetic activity. The aim of the work is 
oral drug delivery Systems time as best kind of approach for delivering 
various drugs but certain drugs given by oral route undergo first pass 
metabolism which leads to low bioavailability, making them less effective. 
To overcome this novel oral drug delivery Systems, ie, chewing gums 
were developed as an alternate for conventional oral systems. These were 
used for both systemic and local delivery of drugs. Domperidone, an anti 
emetic drugs, is poorly water soluble, to enhance it’s solubility, solubilizers 
were used in various rations for the obtained formulations, evaluation 
studies were carried out. Weight Variation, drug content values were found 
to be within standard limit prescribed. In vitro studies were carried out 
using modified disintegration apparatus and all the formulations showed 
release between 70-90%.Ex Vivo studies were carried out using porcein 
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buccal mucosa & up to 60% of drug release was found. Drug excipient 
compatibility was studied by FTIR studies. 
 Ganesh S. Bhoi * et al (2014) formulated and evaluation of medicated 
chewing gum chlorpheniramine male ate. Chewing gum is the convenient 
and effective means of rapidly administering chlorpheniramine male ate, 
as it’s readily soluble, permeable and used to relieve symptoms of allergy, 
hay fever and common cold. This medicated chewing gum was prepared 
by direct compression method using gum base, sorbitol, mannitol, 
magnesium stearate, lecithin, menthol. This method consists of gum base 
& lecithin like 30-35-40% and 5-10-15% accordingly. In this formulation 
soya lecithin was used as a plasticizer & it was  found that it acted on the 
drug release to some extent. When concentration of soya lecithin was 
increased, drug release was also found to be increased.  
 Say ed abolfazl  mostafavi * et al (2014) developed the formulation 
development and evaluation of metformin chewing gum with bitter taste 
masking. Medicated chewing gums are intended to be chewed and act 
either locally, absorbed via the buccal mucosa (or) swallowed with saliva. 
metformin hydrochloride (250 mg) with suitable sweeteners was mixed 
manually for 5 minutes. This mixture was spray dried; freeze dried, (or) 
directly mixed with chewing gum base. Glycerin, xylitol and menthol were 
added & the produced paste was kept in the freezer for2hto be stable. As 
the metformin shows bitter taste, we tried to mask this unpleasing taste 
using different method the releasing pattern was evaluated by using a 
mechanical chewing machine. The best formulation with the optimized 
releasing pattern, suitable physico chemical properties were identified as 
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well, pleasant taste were selected. Content uniformity, releasing percent, & 
other physico chemical properties were identified Taste, flavor, and 
appearance characteristics were evaluated by using a self – made 
questionnaire based on the hedonic test method. The chewing gum 
dosage content was about 86.2% the release rate of metformin chewing 
gum was about 70% after 5 min of mastication masking the bitter taste of 
drug was achieved by using acesulfame – isomalt as sweeteners and 
prepared it by freeze drying equipment. Metformin chewing gum had 
suitable appearance and appropriate invitro characteristics that follow the 
pharmacopeia suggestions. This chewable gum showed bitterness 
suppression with a suitable release rate.  
 Hem ant Ks Yadav*et, al (2014) developed the formulation and 
evaluation of medicated chewing gum as antiplaque and antibacterial 
agent. The aim of this study was to formulate chewing gum using 
chlorhexidine and chitosan and to prove its antibacterial and anti plaque 
properties effectively at low doses of chlorhexidine. Chewing gums were 
prepared by using chlorhexidine and various proportions of gum base and 
chitosan. Hot melt technique was used to prepare chewing gums. The 
prepared gums were evaluated for physical parameters, compatibility 
studies, drug content, moisture content, stability studies & in vitro drug-
release testing. The test group administered chewing gums containing 
chlorhexidine, with & without the polymer, while the control group 
administered dummy chewing gums. The volunteers were visually 
examined for presence (or) absence of gingival erythema, gingival edema 
and gingival bleeding & the antibacterial activity was assessed by the 
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reduction in bacterial count in the plaque samples. As the proportion of 
gum base was increased, an increase in hardness of the chewing gum 
was observed. The formulation, which contains highest concentration of 
chitosan, showed more in vitro release compared to other formulation, 
Analysis of variance revealed significant differences between subjects 
receiving F1 & F5 for antiplaque activity. The   agent which showed a 
better reduction in the bacterial count and gingival index. The dose of 
chlorhexidine can be reduced significantly when used along with chitosan. 
chitosan containing chewing gum has a greater antibacterial effect 
compared with gum containing only chlorhexidine. 
 Ritesh Kumar et,al (2014) Reviewed on chewing gums, chewing gums 
are mobile drug delivery systems. Unlike chewable tablets medicated 
gums are not supposed to be swallowed & may be removed from the site 
of application without resort to invasive means & medicated chewing gum 
MCG is solid, single dose preparation. As for as patient convenience is 
concerned it’s discrete and easy administration without Water promotes 
higher compliance. Since it can be taken any were, a chewing gum 
formulation is an excellent choice for acute medication. The ad vantages 
for children and for patients who find swallowing tablets difficult are 
obvious. The medicated chewing gums are solid, single dose preparations 
with a base consisting mainly of gums that are intended to be chewed, but 
not swallowed. They contain one (or) more active substances, which are 
released by chewing &are intended to be used for local treatment of mouth 
diseases (or) systemic delivery after absorption through the buccal 
mucosa. This concept is supported by statements that chewing sugar free 
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gum can help reduce the risk of dental caries (cavities).the objective of this 
systematic study is to appraise existing evidence concerning a possible 
therapeutic effect of sugar free chewing gum for patients. MCG represents 
the newest system with potential uses in pharmaceutical, over the counter 
medicines and nutraceuticals.  
 Paresh Mohan * et al (2013) developed the formulation and evaluation of 
medicated chewing gum of metaclopramide. A new attempt has been 
made to formulate new chewing gum device for metaclopramide in the 
form of tablet, by direct compression using conventional pharmaceutical 
equipment. Different gum with varying concentration of plasticizers like 
glycerol and castor oil were formulated. Better consistency of formulation 
and faster release of drug in saliva was obtained with glycerol F(3) and 
castor oil F(2) But castor oil show optimum result against test showed 85% 
of drug absorbed within 15 min when available to the buccal mucosa at pH 
5.5, Hence, metaclopramide chewing gum can be considered as a better 
formulation for the buccal drug delivery system, in which drug is absorbed 
buccally and reaches the systemic circulation via jugular vein.  
 Dr. Abolfazl Aslani, * et al (2012) developed the design, formulation and 
evaluation of nicotine chewing gum. Nicotine replacement therapy (NRT) 
can help smokers to quit smoking. However, the bitter taste of such gums 
may compromise their acceptability by patients. This study was, therefore, 
designed to develop 2and 4mg nicotine chewing gums of pleasant taste, 
which satisfy the consumers the most. Most formulations released 79-83% 
of their nicotine content  within 20minute. Nicotine containing sugar coated 
gums in which aspartame as sweetener and cherry and eucalyptus as 
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flavoring agents were incorporated had optimal chewing hardness, 
adhering to teeth, and plumpness characteristics as well as the most 
pleasant taste and highest acceptability to smokers nicotine gums of 
pleasant taste may, therefore, be used as NRT to assist smokers quit 
smoking.  
 Sabera Khatun * et al (2012) reviewed medicated chewing gum: An 
unconventional drug delivery system. It’s considered to be a potential and 
convenient modified release drug delivery system which can be used in 
pain relief medication, smoking cessation, travel illness, freshening of 
breath, prevention of dental caries, alleviation of xerostomia, vitamin (or) 
mineral supplementation etc. This formulation offers both local and 
systemic effects and has a range of advantages over conventional oral 
solid dosage forms. Medicated chewing gum has drawn attention to the 
researchers as potential drug delivery system and it could be a 
commercial success in near future.  
 Swami N.G.N* et al (2012) developed the formulation and 
characterization of medicated chewing gums of Dextromethorphan Hydro 
bromide. Dextromethorphan hydro bromide chewing gum formulations 
were made employing pharmagum M as the base with an aim to overcome 
the first pass effect, reducing the risk of overdosing, ease of administration 
and for achieving faster systemic absorption. The prepared medicated 
chewing gums were 7evaluated for various precompression and post 
compression parameters. The formulations were found to be stable in 
respect to physical parameters and no significant deviations were seen in 
respect to in vitro drug release characteristics.  
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 Abolfazl Aslani *et al (2012) developed the design, formulation and 
evaluation of caffeine chewing gum. In other dosage forms caffeine 
increases alertness and decrease fatigue. Aim of this study to design a 
new formulation of caffeine chewing gum with desirable taste and assess 
its physico chemical properties. It is prepared by softening of gum bases 
and the mixing with other formulation ingredients. After making all 
formulations, choose the best formulation in organoleptic properties. The 
gum released about 90% of their own drug content after 30 minutes. In this 
study, caffeine gums with suitable and desirable properties (good taste& 
satisfactory release) were formulated. 
 Bhaskar D.Ingole*et al (2012) reviewed, chewing gum: A mobile drug 
delivery system. It’s a potentially useful means of administering drugs 
either locally (or) systemically via the oral cavity. The medicated chewing 
gum has through the years gained increasing acceptance as a drug 
delivery system. Several ingredients are now incorporated in medicated 
chewing gum; (e.g.) fluoride for prophylaxis of dental caries, chlorhexidine 
as local disinfectant, nicotine for smoking cessation, aspirin as an 
analgesic, as caffeine as stay alert  preparation. MCGs are solid, single 
dose preparation with a base consisting mainly of gums that are intended 
to be chewed but not swallowed. The contain one (or) more active 
substances which are released by chewing and are intended to be used 
for local treatment of mouth diseases (or) systemic delivery after 
absorption through the buccal mucosa.  
 Farhad Mehta*et al (2011) developed the formulation and 
characterization of medicated chewing gum drug delivery of 
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diphenhydramine hydrochloride. The release of a drug from chewing gum 
is dependent upon its water solubility. Water soluble substances are 
released rapidly and completely from chewing gum and methods are 
available which retard their release from chewing gum and require special 
formulation techniques to produce satisfactory release profile. Studies 
evaluating the potential application of medicated and non-medicated 
chewing gum in the oral cavity are described. Specific examples of the use 
of chewing gum as a delivery system for dental health, smoking cessation 
and antifungal therapy are cited. Few drugs are suitable candidates for the 
intention of their systemic delivery. Know-how derived from the 
development and manufacture of already existing medicated & non-
medicated chewing gum, supplemented with today’s knowledge of the 
principles of pharmaceutical formulation, constitute the basis for the 
development of the medicinal chewing gum of tomorrow.  
 Vipul P.Patel *et, al (2011) reviewed on medicated chewing gum. 
Chewing gums are mobile drug delivery systems. It’s a potentially useful 
means of administering drugs either locally (or) systemically via, the oral 
cavity the medicated chewing gum has through the year gained increasing 
acceptance as a drug delivery system.  
 M.Bolan *et al (2008) developed the erosive effects of acidic center-filled 
chewing gum on primary and permanent enamel. The aim of this study 
was to evaluate the erosive potential of acidic filling of chewing gum in 
primary and permanent enamel. Eighty enamel blocks (40 permanent and 
40 permanent teeth) were used and randomly distributed into eight groups. 
All groups showed a significant decrease in surface micro hardness. There 
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was a statistically significant difference between D1, D2, D3, and D4, 
regarding the concentration, then the diluted acid content was associated 
with a greater decrease in micro hardness. It’s concluded that the acidic 
filling of a chewing gum reduced the micro hardness of primary and 
permanent enamel.  
 Alasdair McGowan * et al (2006) developed the pharmacokinetics & 
pharamacodynamics of the tetracycline’s including glycyclines the 
pharmacokinetics of tetracycline’s and glycyclines are described in three 
groups. Groups1, the oldest group represented by tetracycline, 
oxytetracyclines, chlortetracycline, demeclocycline, lymecycline, 
methacycline and rolitetracycline is characterized by poor absorption after 
food. Group2, represented by deoxycycline, is more reliably absorbed 
orally, while group3, represented by the glycycline. Tigecycline is inject 
able only, with an improved antibacterial spectrum compared with the 
tetracycline’s. Though incompletely understood, the pharamacodynamic 
properties of the tetracycline’s & glycylcyclines. 
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CHAPTER - IV 
AIM OF WORK 
 Oral drug delivery systems have proven time as best kind of approach for 
delivering various drugs. Oral route has been the most commonly adopted 
and most convenient route for the drug delivery. 
 Conventional oral drug delivery systems are tablets and capsules. But they 
have certain disadvantages like some drugs cause gastric irritation, some 
undergo first pass metabolism and difficulty in swallowing for those 
suffering Dysphagia. 
 First pass metabolism which leads to low bio availability, making them less 
effective. To overcome these Novel oral drug delivery systems, i.e. ., 
chewing gums were developed as an alternate for conventional oral 
systems. These were used for both systemic & local delivery of drugs. 
These systems have benefits like increased patient compliance, increased 
bioavailability & self administration. 
 The aim of present study was to design and characterize medicated 
chewing gum for the treatment of bacterial infection using lymecycline as 
model drug. Lymecycline is an Antibacterial agent. 
 It prevents spreading of the infection & the growth of bacterial mainly used 
in conditions such as chronic bronchitis, Lyme disease, dental infections 
and acne. 
 After oral administration it’s rapidly absorbed. Maximum peak plasma 
concentration is reached after approximately 2 hr this model drug is 
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selected for the study in order to overcome the hepatic first pass effect and 
there by possible reduction in the dose. 
 Lymecycline has higher oral bioavailability, less side effects and has quick 
onset of action these factors make lymecycline is suitable candidate for 
formulation of medicated chewing gum used to treat bacterial infection. So 
it’s a drug of choice in Dental infections (Infections in (or) around the 
mouth) 
 Lymecycline is a broad spectrum antibiotic used in mouth disease. It’s 
usually administered orally. It has first pass metabolism and show a very 
poor dissolution rate in order to overcome this problem by preparation of 
medicated chewing gum. 
 Lymecycline inhibits the cell growth by inhibits the cell growth by inhibiting 
translation (protein biosynthesis inhibitors); Tetracycline antibiotic. The 
drug binds reversibly to the 30s subunit of the bacterial ribosome, thereby 
blocking access of the amino acyl/-- RNA to the mRNA – ribosome 
complex at the acceptor site. By, this mechanism, bacterial protein 
synthesis/ is inhibited. 
 To overcome all the drawbacks development of MCG of Lymecycline 
improves the patient compliance. 
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CHAPTER- V 
PLAN OF WORK 
STEP: I 
PRE-FORMULATION STUDIES: 
Standard curves for Lymecycline: 
a. Determination of λ max of Lymecycline in Phosphate buffer pH 6.8. 
b. Calibration curve for the Lymecycline at max in  Phosphate buffer pH 6.8. 
STEP: II 
DRUG- POLYMER INTERACTION STUDIES: 
 Fourier Transform Infrared Spectroscopic (FT-IR) Studies. 
STEP: III 
PREPARATION OF MEDICATED CHEWING GUM BY MELTING METHOD: 
 (Conventional/ traditional method): 
Chewing gums are prepared by melting a gum base at a temperature of 
60-700c until it softens. To this molten mass add liquid glucose & glycerol and mix 
well. Remove the mass from heat and add all other ingredients, mix well, rolled in 
calcium carbonate powder, cut into required size & shape. 
STEP: IV 
CHARACTERIZATION OF LYMECYCLINE MEDICATED CHEWING GUM: 
: Determination of production yield 
 Determination of drug content. 
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 Solubility profile. 
 Invitro release studies of Lymecycline chewing gum. 
 Kinetics of drug release. 
 Stability studies. 
STEP: V 
SELECTION AND EVALUATION OF BEST FORMULATION: 
 Production yield. 
 Solubility profile. 
 In-Vitro drug release studies 
 Release kinetics. 
 Stability studies. 
STEP: VI 
EVALUATION OF BEST FORMULATION: 
 Release kinetics. 
 Fourier transforms infrared spectroscopy (FT-TR) & Stability analysis. 
 Differential scanning calorimetric (DSC) 
 Stability Study 
 Drug content 
 In Vitro drug release studies 
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STEP: VII 
FORMULATION OF LYMECYCLINE CHEWING GUM: 
 Lymecycline chewing gums are formulated by melting method. Required 
quantity of synthetic gum base was taken into a china dish and melted taken into 
a china dish and melted at a temperature of 60-70oc until it softens. To this 
molten mass add required quantity of liquid glucose and glycerol mix it. Remove 
the mass from the heat add all other ingredients mixed well & rolled in calcium 
carbonate powder, cut into six and shape. 
STEP: VIII: 
EVALUATION OF MEDICATED CHEWING GUM: 
a. Compatibility studies: 
 Fourier- transform Infra red spectroscopic (FTIR) studies 
b. Pre Compressional evaluation: 
 Drug content 
c. Pre compressional evaluation of medicated chewing gum: 
 General appearance. 
 Length of chewing gum. 
 Weight variation 
 Drug Content 
 Invitro release studies 
d. Comparison of Invitro release of Lymecycline chewing gum with pure 
drug lymecycline. 
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CHAPTER- VI 
MATERIALS AND EQUIPMENTS 
 
S.NO POLYMER/ EXCIPIENTS MANUFACTURER 
1. Lymecycline 
Gift sample from Madras 
Pharmaceuticals, Chennai, India 
2. Poly Vinyl acetate 
Gift sample from  Madras 
Pharmaceuticals Chennai, India 
3. Betacyclodextrin 
Central Drug House (P) Ltd, 
New Delhi, India 
4. Polyethylene glycol Pharma Fabrikon, Madurai India 
5. Poly Vinyl alcohol Pharma Fabrikon, Madurai India 
6. Cross Povidone Pharma Fabrikon, Madurai India 
7. Glycerol Scientific universal appliances 
8. Sucrose Scientific universal appliances 
9. Calcium Carbonate Scientific universal appliances 
10. Mannitol Scientific universal appliances 
11. Aspartame Madras Pharmaceuticals 
12. Flavor Scientific Universal appliances 
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EQUIPMENTS 
S.NO POLYMER/ EXCIPIENTS MANUFACTURER 
1. Electronics weighing balance A & D Company HR 200, Japan 
2. UV Visible Spectrophotometer Shimadzu, Japan 
3. Hot air oven 
Rands Instruments Chennai, 
India 
4. Digital Scanning Calorimeter DSC 60 Shimadzu 
5. 
Fourier Transform Infrared 
Spectrophotometer 
Shimadzu, Japan 
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CHAPTER- VII 
DRUG PROFILE 
LYMECYCLINE: 
Synonym: 
 Mucomycin, Limeciclina, Tetracycline –L- Methylenelysine  
Structural Formula: 
 
 
 
Empirical Formula: 
 C29H38 N4O10 
Chemical Name: 
 (2S)-6- ((((Z) - ((4s, 4as, 5as, 6s, 12, as)-4 
 (Dimethylamino)-6, 10, 11,12a- tetra 
 Hydroxyl-6- methyl -1, 3, 12 – trioxo-4,4a 
 5,5a-tetrhydro tetracen-2- yildene) 
 -hydroxy methyl) amino) methyl amino)-2-amino hexanoic acid. 
Chemical Data: 
 Boiling Point  : 840.50c at 760mm Hg 
 Melting Point  : Above 2000 6>139oc 
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 Solubility Profile : Very Soluble in Water 
     Slightly Soluble in ethanol (96%) & 
                        Practically insoluble in methylene chloride, ether,   
                                                     chloroform. 
 Description  : Yellow, hygroscopic Powder 
 Bio-availability : 100% (Oral) 
 Protein Binding : 80-90% 
 Half – life   : (10 hours) 7-14 hours 
 PH range  : At all the physiological PH Values 
 Nature  : Yellow, hygro scopic powder 
 Density  : 1.53 
 Flash Point  : 462.1oc 
 Log P   : (Octanol/ Water) Partition Coefficient-3.2 
 Refractivity  : 154.51 m3 Mol-1 
 Polari ability  : 62.88 Ao3 
 Number of rings : 4 
 Excretion  : Kidney 
 Storage  : Amber Vial, -86oc Freezer, under inert atmosphere 
Identification: 
 λmax at 267 nm in UV spectrophotometer 
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Pharmacodynamic Properties: 
 Lymecycline, is a tetracycline bread spectrum antibiotic. It is approximately 
5000 times more soluble than tetracycline base and is unique amongst 
tetracycline’s in that its absorbed by the active transport process across the 
intestinal wall, making use of the same fast and efficient mechanism by which 
carbohydrates are absorbed. It inhibits cell growth by inhibiting translation. 
Mechanism of action: 
 Lymecycline inhibits cell growth by inhibiting translation. It binds to the 30s 
ribosomal subunit & prevents the amino-acyl tRNA from binding to the A site of 
the ribosome. The binding is reversible in nature. Lymecycline is lipophilic and 
can easily pass through the cell membrane (or) passively diffuses through porin 
channels diffuses through porin channels in the bacterial membrane cells 
become resistant to lymecycline by at least two mechanisms: efflux and 
ribosomal protection. In efflux, a resistance gene encodes a membrane protein 
that actively pumps lymecycline out of the cell. This is the mechanism of action of 
the tetracycline resistance gene on the artificial plasmid PBR 322. In ribosomal 
protection, a resistance gene encodes a protein which binds to the ribosome and 
prevents lymecycline from acting on the ribosome. 
Pharmacokinetics: 
 Absorption: 
 Absorption is rapid, effective plasma levels are reached within the first 
hour following drug intake: 
 The peak plasma level is reached within 3 to 4 hours after, oral 
administration. Concurrent milk in take has not been shown to significantly modify 
the absorption of lymecycline. 
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Distribution: 
 Oral administration of 300 mg, in the adult give rise to: 
 A peak plasma level of 1.6 to 4 mg/ml. 
 A highly variable residual concentration (0.29 to 2.19 mg/ml) 
 A plasma half life of approximately 10 hours. 
Repeated administration results in a steady mean plasma concentration 
between 2.3 and 5.8 mg/ml. Wide intra and extra cellular diffusion, under normal 
dosage conditions, results in effective concentrations in most body tissues and 
fluids, and notably in the lungs, bones, muscles, liver, bladder, prostate, bile and 
urine. 
Excretion/ elimination: 
 The product is principally excreted in urine and secondarily in the bile. 
About 65% of the administered doses are eliminated within 48 hours. 
Dosage forms: 
 Capsules 300 mg, 408 mg 
Therapeutic Indications: 
 Lymecycline is primarily indicated in conditions like acne vulgaris, 
Amoebiasis, Bacterial infections, Endocarditis, Pneumonia, Rickettsiae, Syphilis, 
& can also be given in adjunctive therapy as an alternative drug of choice in 
acute sinusitis, chronic bronchitis, soft tissue infections. 
Dose: 
 408 mg twice a day 
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Adverse effects: 
 The severe (or) irreversible adverse effects of lymecycline, which given 
rise to further complications, include. Increased blood urea nitrogen, Azotemia, 
Acidosis, Azotemia. Lymecycline produces potentially life- threatening effects 
which include anaphylaxis, acute hepatic dysfunctioning which are responsible 
for the discontinuation of Lymecycline therapy. Nausea, Diarrhea, stomach pain. 
Preparations: 
 Capsules 
Storage:  
 Store below 25oc protect from sunlight. 
Contra- indications: 
 Lymecycline is contra-indicated in conditions like systemic lupus 
erythematosus. 
Brand Names 
 Dam elium  (Act avis group) 
 Limeclin (Mediderm) 
 Tetralisal (Gal derma) 
 Tetraysal 
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CHAPTER- VIII 
EXCIPIENTS PROFILE  
POLY VINYL ALCOHOL 
Synonym: 
 airvol 
 Elvanol 
 Gohsenol 
Empirical Formula: 
 (C2H4O) n 20000-200000 
Structural Formula: 
 
 
Functional Category: 
 Coating agent 
 Lubricant 
 Stabilizing agent 
 Viscosity- increasing agent. 
Applications: 
 Poly vinyl alcohol is used primarily in topical pharmaceutical and 
ophthalmic formulations. 
 It’s use as a stabilizing agent for emulsions 
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Description: 
 Ploy vinyl alcohol occurs as odorless, white to cream colored granular 
powder. 
Solubility: 
 Soluble in water, slightly soluble in ethanol, insoluble in organic solvents. 
Storage Conditions: 
 Poly vinyl alcohol is stable when stored in a tightly sealed container cool, 
dry place. 
 Aqueous solutions are stable in corrosion- resistant sealed container. 
Safety: 
 PVA is generally considered a non-toxic material. 
 It’s non- irritant to the skin and eyes at concentrations up to 10% 
concentrations up to 7% are used in cosmetics. 
Handling Precautions: 
 Protection & gloves recommended. 
 PVA dust may be an irritate on inhalation. 
 Handle in well ventilated environment. 
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ASPARTAME 
Synonyms: 
 Aspartyl Phenyl amine methyl ester 
 Nutra Sweet 
 Pal Sweet 
 Canderel 
 Equal 
 Pal Sweet diet 
Chemical Name: 
 N-a-L- Aspartyl- L- Phenyl -alanine 1-methyl ester 
Empirical formula and molecular weight: 
 C14H18N2o5 294.31 
Structural Formula 
 
 
 
 
Functional Category: 
 Sweetening agent 
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Description: 
 Aspartame occurs as an off white, almost odorless, crystalline powder with 
an intensely sweet taste. 
Density: (true) 
 1.347 g/cm3 
Melting Point: 
 246-247oc 
Solubility: 
 Slightly soluble in ethanol (95%); sparingly soluble in water. At 20oc the 
solubility is 1% acidic PH, e.g., at PH1 and 20oc solubility is 10% W/v. 
Stability and Storage Conditions: 
 Aspartame is stable in dry conditions. In the presence of Moisture, 
hydrolysis occurs to form the degradation products L-asparty1-L-
Phenylalanine & 3 benzyl -6- car boxy methyl -2, 5- diketopiperazine. A 
third- degradation product is also known, B-L-aspartyl- L Phenylalanine 
methyl ester. 
 Aspartame degradation also occurs during prolonged heat treatment 
losses of aspartame may be minimized by using processes that employ 
high temperatures for a short time followed by rapid cooling. 
 The bulk material should be stored in a well closed container, in a cool, dry 
place. 
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Method of manufacture: 
 Aspartame is produced by coupling together L-phenylalanine (or L-Phenyl 
alanine methyl ester) and L- aspartic acid, either chemically (or) enzymatic ally. 
The former procedure yields both the sweet a- aspartame from which the 
aspartame has to be separated and purified. The enzymatic process yields only 
aspartame. 
Handling precautions: 
Observe normal precautions appropriate to the circumstances and quantity 
of material handled.measures should be taken to minimize the potential for dust 
explosion.eye protection is recommended. 
Applications: 
 Intense sweetening agent in beverage products,food products and table-
top sweeteners and in pharmaceuticalpreparations including 
tablets,powder mixes and vitamin preparations. 
 Therapeutically,aspartame has also been used in the treatment of sickle 
cell anaemia. 
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MANNITOL 
Synonyms: 
 Cordycepic acid, Manna Sugar, D- Mannite, Mannite, Mannogem,Pearlitol. 
Chemical Name: 
 D- Mannitol 
Empirical Formula & Molecular Weight: 
 C6 H14 O6 182.17 
Structural Formula: 
  
 
 
Functional Category: 
 Diluents, Diluents’ for lyophilized preparations, sweetening agent, tablet 
and capsule diluents; tonicity agent. 
Description: 
 Mannitol is D- Mannitol. It’s a hexahydric alcohol related to mannose and 
is isomeric with sorbitol. 
 Mannitol occurs as a white, odorless, crystalline powder (or) free- flowing 
granules. It has a sweet taste, approximately as a sweet as glucose & half 
as sweet as sucrose, and imparts a cooling sensation in the month. 
Microscopically, it appears as orthorhombic needless when crystallized 
from alcohol. Mannitol shows polymorphism. 
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Density: (True) 
 1.514 g/Cm3 
Density: (tapped) 
 166-168oc 
Solubility: 
 Solvent  Solubility at 20oc 
 Alkalis Soluble 
 Ethanol (95%) 1 in 83 
 Ether Practically insoluble 
 Glycerin 1 in 18 
Stability and storage conditions: 
 Mannitol is stable in the dry state and in aqueous solutions. In solution, 
Mannitol is not attacked by cold, dilute acids or alkalis or by atmospheric oxygen 
in the absence of catalysts. Mannitol does not undergo Millard reactions. 
 The bulk material should be stored in a well closed container in a cool, dry 
place. 
Incompatibilities: 
 Mannitol is incompatible with xylitol infusion and may form complexes with 
some metals such as aluminum copper and iron. 
Method of manufacture: 
 Mannitol may be extracted from the dried sap of manna & other natural 
sources by means of hot alcohol (or) other natural sources by means of hot 
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alcohol (or) other selective 501 vents. It’s commercially produced by the catalytic 
(or) electrolytic reduction of mono saccharides such as mannose and glucose. 
Safety: 
 Mannitol is a naturally occurring sugar alcohol found I animals and plants; 
it’s present in small quantities in almost all vegetables. Laxative effects may 
occur if mannitol is consumed orally in large quantities. 
Handling precautions: 
 Observe normal precautions appropriate the circumstances and quantity of 
material handled. Mannitol may be irritant to the eyes; eye protection is 
recommended. 
Applications in pharmaceutical formulation: 
 Mannitol is widely used in pharmaceutical formulations and food products. 
In pharmaceutical preparations it’s primarily used as a diluents (10-90% 
W/w) in tablet formulations, where it’s of particular value since it’s not 
hygroscopic and may thus be used with moisture- sensitive active 
ingredients/ 
 Mannitol may be used in direct compression tablet applications, for which 
the granular and spray dried forms are available, (or) in wet granulations. 
Granulations containing mannitol have the advantage of being dried easily, 
 Mannitol is also used as diluents in rapidly dispersing oral dosages 
forms. 
 It’s used in food applications as a bulking agent.   
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POLY ETHYLENE GLYCOL 4000 
Synonyms: 
 Carbowax 
 Carbowax Sentry 
 Lipoxol 
 Pluriol E 
 Poly oxy ethylene glycol 
Empirical Formula: 
 H (OCH2CH2) nOH 
Molecular weight: 
 3000-4800 g/Mol 
Structural Formula: 
  H     H 
  I     I 
 OH- C – (CH2-O-CH2)   m- C- OH 
  I     I 
  H     H 
Functional Category: 
 Ointment base, Plasticizer, Solvent, Suppository base, tablet & capsule 
lubricant. 
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Description: 
 Polyethylene glycol as being an addition polymer of ethylene oxide and 
water. Poly ethylene glycol grades 200-600 are liquids, grades 1000& 
above are solids at ambient temperatures. 
 Liquid grades (PEG 200-600) occur as clear, colorless (or) slightly yellow 
colored, viscous liquids.  They have a slight but characteristic odor. Grads 
of PEG 6000& above are available as free flowing milled powders. 
Pharmacopeial Specifications 
Solubility: 
 All grades of polyethylene glycol are soluble in water & miscible in all 
proportions with other polyethylene glycols (after melting, if necessary) 
 Liquid poly ethylene glycols are soluble in acetone, alcohols, benzene, 
glycerin & glycols. 
 Solid poly ethylene glycols are soluble in acetone, dichloromethane, 
ethanol (95%) & methanol they are slightly soluble in aliphatic 
hydrocarbons & ether, but insoluble in fats, fixed oils, & mineral Oil. 
Surface Tension: 
 44 mN/m (44 dynes/cm) 
 Density  :  1.080 (g/cm3)  
 Freezing Point : 53-59 
 Hydorxyl Value : 25-32 
 Viscosity : 110-170 
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Stability and storage conditions:  
 Polyethylene glycols are chemically stable in air & in solution, although 
grades with a molecular weight less than 2000 are hygroscopic. 
 PEG should be stored in well- closed containers in a cool, dry place. 
Stainless steel, aluminum, glass (or) linted steel containers, are preferred 
for the storage of liquid graders. 
Method of manufacture: 
 Polyethylene glycols are Condensation polymers formed by the reaction of 
ethylene oxide & water under pressure in the presence of a catalyst. 
Safety:  
 Nontoxic & Non Irritant materials. 
 Oral administration of large quantities of PEGs can have a laxative effect. 
 Topical preparations containing poly ethylene glycols. 
 Should therefore be used cautiously in patients with renal failure, 
extensive burns (or) open wounds. 
 The who has set an estimated acceptable daily intake of polyethylene 
glycols at up to 10mg/kg body weight. 
Handling Precautions: 
 Should observe normal precautions appropriate to the circumstances and 
quantity of material handling protection is recommended. 
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Applications: 
 PEGs are widely used in a variety of pharmaceutical formulations including 
parental, topical, ophthalmic, oral & rectal preparations. 
 It has been used experimentally in biodegradable polymeric matrices used 
in controlled release systems. 
 The poly ethylene glycols are water soluble & are easily removed from the 
skin by washing, making them useful as ointment bases. 
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SUCROSE 
Synonyms: 
 Beet sugar 
 Cane sugar 
 Refined Sugar 
Empirical formula: 
 C12H 22 O11 
Chemical Name: 
 B-D- Fructofuranosyl – a- D- glucopyranoside 
Structural formula: 
 
 
 
 
Functional Category: 
 Base for medicated confectionery. 
 Coating agent 
 Granulating agent 
 Sugar Coating adjacent 
 Suspending agent 
 Tablet binder 
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Description: 
1. Sucrose is a sugar obtained from sugar cane 
(SaccharumofficinarumLinne) (FAM: Graminae) sugar beet (Beta 
Vulgar is Linne) (Fam. Chenopodiaceae), & other sources. It 
contains no added substances. Sucrose occurs as colorless 
crystals, as crystalline masses (or) as a white crystalline powder, 
it’s a odorless & has a sweet taste. 
Pharmacopeial specifications Solubility: 
 Solvent   :  Solubility at 20oC unless otherwise stated 
 Chloroform : Practically Insoluble 
 Ethanol  : 1 in 400 
 Ethanol (95%) : 1 in 170 
 Water  : 1 in 0.5 
    1 in 0.2 at 100oc 
Typical Properties: 
Density (bulk) : 0.93 g/cm3 
    (Crystalline sucrose) 
    0.60 g/cm3 (Powdered sucrose) 
Density (tapped): 
 1.03 g/cm3 (crystalline sucrose) 
 0.82 g/cm3 (Powdered Sucrose) 
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Density (true): 
 1.6 g/cm3 
Density (Constant): 
 PKa – 12.62 
Flow ability: 
 Crystalline sucrose is free flowing, whereas powdered sucrose is a 
cohesive solid. 
Melting Point: 
 160 – 186o C (with decomposition) 
Moisture content: 
 Finely divided sucrose is hygroscopic and absorbs up to 1% water 
Applications: 
 It’s used in large volume infusions. 
 Sucrose syrups are also widely used as vehicles in oral liquid dosage 
forms to enhance stability (or) to increase viscosity. 
 Sucrose has been used as a diluents in freeze- dried protein products. 
 Sucrose syrups are used as tablet- coating agents at concentrations 
between 50% & 67% w/w with higher concentrations, partial inversion of 
sucrose which makes sugar coating difficult 
 Sucrose is used in foods & confectionery & therapeutically in sugar pastes 
that are used to promote wound healing. 
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Beta Cyclodextrins 
Synonym: 
 B- Cyclodextrin beta- cycloamylose 
 Beta- dextrin 
 Beta dexum 
Empirical Formula: 
 C42H7035 
Molecular Weight: 
 1135 g/Mol 
Structural Formula: 
 
 
 
 
 
Functional Category: 
 Solubilizing agent 
 Stabilizing agent 
Description: 
 Cyclodextrins occur as white, practically odorless, fine crystalline powders, 
having a slightly sweet taste. Some cyclodextrin derivatives occur as amorphous 
powders. 
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Solubility: 
       Soluble 1 in 200 parts of propylene glycol. 
Stability and storage conditions: 
      It is stable in the solid state if protected from high humidity.It should be stored 
in a tightly sealed container , in a cool, dry place. 
Handling precautions: 
      Should be handled in a well ventilated environment. 
Applications: 
 Cyclodextrins may be used to form inclusion complexes with a variety of 
drug molecules, resulting primarily in improvements to dissolution and bio 
availability. 
 Primarily used in tablet and capsule formation. 
 Cholesterol free products. 
 Bioavailability enhancer. 
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CALCIUM CARBONATE 
Synonyms: 
 Micro mite 
 Pharma- Carb 
 Precipitated Carbonate of line 
 Precipitated chalk 
Chemical Name: 
 Carbonic acid, calcium salt (1:1) 
 Empirical Formula and molecular weight: 
 
 Caco3 100.09 
Structural Formula: 
 
 
 
Functional Category: 
 Buffering agent 
 Coating agent 
 Opacifier 
 Tablet and capsule diluents therapeutic agent 
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Description: 
 Calcium carbonate occurs as an odorless and tasteless white power (or) 
crystals 
Density: (bulk) 
 0.8 g/cm3 
Density: (tapped) 
 1.2 g/cm3 
Melting Point : 
 Decomposes at 825oC 
Solubility: 
 Practically insoluble in ethanol (95%) and Water Solubility in water is 
increased by the presence of ammonium salts (or) carbon dioxide the presence 
of alkali hydroxides reduces solubility. 
Stability and storage conditions: 
 Calcium carbonate is stable & should be stored in a well- closed container 
in a cool, dry place. 
Incompatibilities: 
 Calcium carbonate is prepared by double decomposition of calcium 
chloride and sodium bi carbonate in aqueous solution. Density and fineness are 
governed by the concentrations of the solutions. Calcium carbonate is also 
obtained from the naturally occurring minerals, aragonite, calcites and vaterite. 
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Safety: 
 Calcium carbonate is mainly used in pharmaceutical formulations and is 
generally regarded as a non toxic material. Calcium carbonate administered 
orally may cause constipation and flatulence. 
Handling Precautions: 
 Observe normal precautions appropriate to the circumstances & quantity 
of material handled. Calcium Carbonate may be irritant to the eyes and on 
inhalation. Eye protection, gloves, and a dust mask are recommended. Calcium 
carbonate should be handled in a well ventilated environment. 
Applications: 
 Calcium carbonate, employed as pharmaceutical excipient. 
 Mainly used in solid dosage forms as a diluents. 
 It’s also used as base for medicated dental preparations, as a buffering 
agent and as a dissolution and in dispersible tablets. 
 Calcium carbonate is used as a bulking agent in tablet sugar coating 
processes and as an pacifier in tablet film coating. 
 Calcium carbonate is also used as a food additive and therapeutically as 
an antacid and calcium supplement. 
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Glucose, Liquid 
Synonyms: 
 Corn Syrup 
 Floys 
 Glucomalt 
 Glucose Syrup 
 Glucosweet 
 My lose 
 Starch syrup 
Chemical Name: 
 Liquid glucose 
Empirical formula and Molecular weight: 
 C6H14O7 198.171 g/mol 
Structural Formula: 
 
 
 
Functional Category: 
 Coating agent, sweetening agent, tablet binder 
Molecular weight: 
 198.17116 g/mol
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Description: 
 Liquid glucose is an aqueous solution of several compounds, principally 
dextrose, dextrin, fructose and maltose, with other oligo saccharin and 
polysaccharides. It’s a colorless odorless, and viscous sweet tasting liquid, 
ranging in color from colorless to straw- colored. 
Density: 
 Miscible with water, partially miscible with ethanol (90%) 
Stability and storage conditions: 
 Liquid glucose should be stored in a well closed container in a cool, dry 
place. Elevated temperature will cause discoloration. 
Incompatibilities: 
 Incompatible with strong oxidizing agents. 
Method of Manufacture: 
 Liquid glucose is prepared by the incomplete acidic (or) enzymatic 
hydrolysis of starch. 
Safety: 
 Liquid glucose is used in oral pharmaceutical formulations and 
confectionery products and is generally regarded as a nontoxic and non irritant 
material. It may be consumed by diabetics. 
Handling Precautions: 
 Observe normal precautions appropriate to the circumstances and quantity 
of material handled. 
CHAPTER-VII                                                                       EXCIPIENTS PROFILE 
DEPT.OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.  Page 74 
 
Applications in Pharmaceutical formulation: 
 Liquid glucose is used as a base in oral solution and syrups and also as a 
granulating and coating agent in tablet manufacture. 
 In sugar solutions for tablet coating liquid glucose is used to retard the 
crystallization of the sucrose. 
 Liquid glucose is also used in confectionery products. 
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CROS POVIDONE 
Synonyms: 
Cross linked povidone poly vinyl poly pyrrolidone PVPP 
Structure: 
                              
Empirical Formula & Molecular Weight:  
 (C6H9No) n 1000-000 
 Crospovidone is a water insoluble synthetic cross linked homopolymer of  
N-vinyl- 2 – Pyrrolidone. An exact determination of the molecular weight has not 
been established because of the insolubility of the material. 
Functional Category: 
 Tablet Disintegrant 
Description: 
 Crospovidone is a white to creamy- white, finely divided, free- flowing, 
practically tasteless, odorless (or) nearly, odorless, hygroscopic powder. 
Typical Properties: 
Acidity/ alkalinity: 
 PH- 5.0-8.0 (1% w/v aqueous slurry) 
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Density: 
 1.22 g/cm3 
Moisture Content: 
Maximum moisture sorption is approximately 60% 
Solubility: 
Practically insoluble in water & most common organic solvents. 
Stability & Storage conditions: 
 Crospovidone is hygroscopic; it should be stored in an airtight container in 
a cool, dry place. 
Incompatibilities: 
 Crospovidone is compatible with most organic and inorganic 
pharmaceutical ingredients. When exposed to a high water level, crospovidone 
may form molecular adduct with some materials. 
Method of Manufacture: 
 Acetylene and formaldehyde are reacted in the presence of a highly active 
catalyst to form butynediol, which is hydrogenated to butanediol& then 
cyclodehydrogenated to form butyrolactone. Pyrrolidone is produced by reacting 
butyrolactone with ammonia. This is followed by a vinylation reacting in which 
pyrrolidone& acetylene are reacted under pressure. The monomer vinyl 
pyrrolidone is then polymerized in solution, using a catalyst. Crospovidone is 
prepared a Popcorn polymerization Process. 
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Safety: 
 Crospovidone is used in oral pharmaceutical formulations and is generally 
regarded as a non toxic & non irritant material. 
Handlings Precautions: 
 Observe normal precautions appropriate to the circumstances and 
quanitity of material handled Eye protection & a dust mask are recommended. 
Applications: 
 Tablet disintegrate 
 Dissolution agent 
 It’s also used as a solubility enhancer. 
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Glycerol 
Synonyms: 
 Concentrated glycerin 
 Glycerolum 
Empirical Formula: 
 C3H8O3 92.09 
Chemical Name: 
 Propane -1, 2, 3 – triol (56-81-5) 
Structural Formula: 
 
 
 
Functional Category: 
 Antimicrobial Preservative 
 Emollient 
 Humectants 
 Plasticizer 
 Solvent 
 Sweetening agent 
 Tonicity agent 
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Applications: 
 Glycerin is used in wide variety of pharmaceutical formulations including 
oral, otic, opthalmic, topical &Parentral preparations. 
Descriptions: 
 Glycerin is a clear, colorless, odorless, viscous, hygroscopic liquid, it has a 
sweet taste. 
Solubility: 
 Soluble in 95% ethanol, Slightly soluble in acetone, practically insoluble in. 
Boiling point  : 290oC (with decomposition) 
Density  : 1.2656 9/cm3 at 15oC 
    1.2636 9/cm3 at 20oC 
Hygroscopicity : Hygroscopic 
Melting Point  : 17.8oC 
 Glycerin is hygroscopic. Pure glycerin is not prone to oxidation by the 
atmosphere under ordinary storage conditions but it decomposes on heating, with 
the evolution of toxic aerolein. Mixtures of glycerin with water, ethanol (95%), & 
Propylene glycol are chemically stable. 
 Glycerin may crystallize if stored at low temperature; the crystals do not 
melt until warmed to 20oC. 
 Glycerin should be stored in an airtight container, in a cool, dry place. 
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Incompatibilities: 
 Glycerin may explode if mixed with strong oxidizing agents such as 
chromium trioxide, potassium chlorate (or) potassium permanganate. 
Safety: 
 Glycerin is used in a wide variety of pharmaceutical formulations including 
oral, opthalmic, parental, and topical preparations. Adverse effects are 
mainly due to the dehydrating properties of glycerin. 
 Oral doses are demulcent and mildly laxative in action large doses may 
produce headache, thirst, nausea, and hyperglycemia. 
 When used as an excipient (or) food additive, glycerin regarded as a non 
toxic&non irritant material. 
Handling precautions: 
Observe normal precautions appropriate to the circumstances and quantity 
of material handled. Eye protection and gloves are recommended Glycerin is 
combustible and may react explosively with strong oxidizing agents. 
Applications, in Pharmaceutical formulation: 
 Glycerin is used in a wide variety of pharmaceutical formulations including 
oral, otic, opthalmic, topical, and parental preparations. 
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CHAPTER – X 
RESULTS AND DISCUSSION 
I. STANDARD CURVES FOR LYMECYCLINE 
a. Preparation of Calibration medium: 
The calibration medium pH (6.8) were prepared by using phosphate buffer 
as per the IP procedure (I.P. 2014) 
b. Estimation of absorption maximum (λmax): 
The λmax of Lymecycline was estimated by scanning the 10µg/ml 
concentration of the drug solution in buffer solution of phosphate pH 6.8. It 
showed the λmax (Narendrachary, et al., 2012) in phosphate buffer solution of pH 
6.8 and the results were tabulated Figure 1. 
c. Preparation of standard curves: 
The standard curves of Lymecycline prepared by using phosphate buffer 
pH (6.8}. The linear correlation coefficient was found to be 0.999 for pH (6.8) 
Lymecycline obeys the Beer’s law within the concentration range of 2 to 10µg/ml 
Figure 2. 
II. INFRARED (IR) SPECTROSCOPIC STUDIES: 
Infrared (IR) spectroscopic studies were carried out to confirm the 
compatibility between drug and the polymers used for the preparation of the 
chewing gum. The IR studies were performed for pure drug polymers and 
physical mixture of drug with polymers. The spectra studies at 4000cm-1 to 
400cm-1. The principal peaks for pure drug were observed at wave numbers 3290 
cm-1, 2108 cm-1, 1334 cm-1.  
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S.No Functional Groups Range Wave Numbers 
1. N – H Stretching  3300-3500 cm-1 3290 cm-1 
2. C  C Stretching  2140-2100 cm-1 2108 cm-1 
3. C – N Stretching 1360-1080 cm-1 1334 cm-1 
 
It was found from the spectra that there was no major shifting as well as 
any loss of functional peaks in the spectra of drug, polymers and physical mixture 
of drug with polymers. This clearly indicated that there was no interaction 
between the drug and the polymer and the drug was present in its unchanged 
form. 
III. DIFFERENTIAL SCANNING CALORIMETRIC STUDIES (DSC): 
Differential scanning calorimetric studies (DSC) are commonly used to find 
out the interactions between the drug and excipients. DSC thermograms of pure 
drug, polymers and its physical mixtures were shown in the table. When 
comparing the thermal behaviors of the pure drug, the physical mixture of drug in 
polymer, analysis of the DSC curves can predict any interactions. DSC thermo 
gram of pure drug (Lymecycline) showed a sharp endothermic peak at No shifts 
in the endothermic peak of Lymecycline was observed in the DSC thermo gram 
of physical mixture of Lymecycline and polymers Lymecycline which suggested 
clearly that there was no interaction between the drug & the polymers and thus 
the drug found to be existed in its unchanged form. (Clarks analysis of drugs and 
poisons, third edition.,&sathish M Havanoor.et al 2014) Figure. 3A. 
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III. FORMULATION OF LYMECYCLINE CHEWING GUM: 
The Lymecycline chewing gum was prepared by Melting method 
(KoppulaRajitha et al., 2016). The principles of this method was based on the 
melting of gum base in a china dish, to this add other ingredients and mixed well 
and rolled in CaCO3 powder, where chewing gum is cut into required size and 
shape. Basic advantage of the melting technique was it is simple and had a low 
cost. Lymecycline chewing gum was prepared by following process: 
 Formulation of Lymecycline chewing gums with polymer. 
 Formulation of chewing gums with lymecycline pure gum. 
 Melting of gum base to obtain the medicated chewing gums. 
Various formulations of Lymecycline chewing gums (F1, F2, F3, F4, F5, 
F6, F7, F8, F9, F10, F11, F12, F13, F14, F15, F16) or F1 to  F16    were 
prepared by using different polymers like (PEG-4000, PVA, Cros povidone,β –
CD)at different concentrations were used. 
IV. CHARACTERIZATION OF LYMECYCLINE CHEWING GUM 
All the formulations were evaluated for its drug content, solubility studies, 
in vitro drug release studies. 
a. Determination of drug content: 
The drug content of all chewing gum formulations (F1 to F16) was in the 
range of    90.82% to 98.03%. The results were shown in table. The results 
suggest that the process employed to prepare the chewing gum shown 
distribution of drug (Figure 5). 
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b. Solubility studies: 
Solubility studies of pure drug (Lymecycline) and selected formulation (F8) 
were shown in Table & figure. The best formulation (F8) Chewing gum 
formulations, shown highest solubility in distilled water as compared with pure 
drug. 
 The solubility of formulations {F8} and pure drug in phosphate buffer pH 
(6.8) were 8.05g/10ml and 9.97g/10ml respectively. Thus the solubility of 
Lymecycline chewing gums was increased approximately by ten folds 
when compared to pure drug. Hence, the noticeable increased saturation 
solubility of Lymecycline in the formulation of chewing gums was mainly 
attributed to the decreased particle size & increased surface area. The 
results can be explained by the Ostwald-Freundlich equation which 
demonstrates that the saturation solubility of the drug increases with 
reduction of particle size (Dianruizhang et al., 2012) 
In vitro dissolution studies: 
The dissolution study was carried out in pH 6.8 for 30 minutes. The invitro 
dissolution studies of all formulations were compared with pure drug. The results 
of in vitro drug release studies from the Lymecycline chewing gums were shown 
in the & in when compared the In vitro release profile of all the formulations are 
significantly greater than that pure drug Lymecycline Figure. 9A. 
Formulations [F1, F2, F3, F4] were prepared using different concentrations 
of polymer shown the percentage drug release of 85.13%, 82.69%, 79.78%, 
75.43% at 30 minutes respectively Figure. 9B. 
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Formulations   [F5,F6,F7,F8] were prepared using different concentrations 
of polymer shown the percentage drug release of 90.28%, 92.89%, 94.26%, 
98.26% at 30 minutes respectively Figure. 9C. 
Formulations [F9, F10, F11, F12] prepared using different concentrations 
of polymer shown the percentage drug release of 90.63%, 85.52%, 80.52%, 
83.47% at 30 minutes   respectively. Formulations [F9, F10, F11, F12] prepared 
using different concentrations of polymers shown the percentage drug release of   
91.76%, 88.59%, 85.39%, 81.96% at 30 minutes respectively Figure. 9D. 
The percentage drug release of all the formulations were found to be in the 
following order. The release rate of the drug from the chewing gums were 
increased, on increasing the polymers concentrations. 
The increased percentage drug release of polymer [β-CD] having 
formulation (F8) indicates that, polymer  was used for the chewing gum 
stabilization as this water soluble polymer offers adequate surface active 
properties and it indicates that they have increased the drug release (Amighi. K     
et al., 2005) The increased percentage drug release of polymer having 
formulation (F8) indicates that, polymer  was used as water soluble compound, in 
order to improve the drug dissolution rate (Noushin Bolourchian et al., 2013). 
COMPARISON OF DISSOLUTION DATA OF LYMECYCLINE CHEWING GUM 
CONTAINING DIFFERENT POLYMERS: 
The chewing gums are prepared with different polymers showed maximum 
drug release of 98.26%whereas chewing gums containing β-cyclodextrins 
Figure. 9A-9D. 
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SELECTION OF BEST FORMULATION 
Among Sixteen formulations, the best was selected on the basis of rapid 
drug release profile, lesser moisture absorption ratio, stickiness is also absent. 
Formulation F8 showed faster drug release rate of  98.26%   in 30 minutes, 
comparatively less moisture absorption ratio of 15%, Nil stickiness and stability is 
maintained during the study period. In these parameter would drive the F8 
formulation as a best comparatively. 
EVALUATION OF BEST FORMULATION 
a. Differential scanning Calorimetric studies: 
Any possible drug polymer interaction can be studies by thermal analysis. 
The DSC thermo gram of Lymecycline exhibited an endothermic peak at 
corresponding to its melting point. The thermogram of the final best formulation of 
Lymecycline with other excipients shows the existence of drug endothermic peak 
within the range which indicated the absence of interaction between the drug and 
other excipients. The DSC thermogram of pure drug and the final best 
formulation is presented in Figure 19. 
b. Fourier transforms infrared (FTIR) spectroscopic studies 
Infrared spectra of the Lymecycline chewing gum showed major peak at                    
indicated that there was no interaction between the drug and the final formulation 
throughout the preparation of medicated chewing gum. The result was shown in 
Figure 3. 
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S.No Functional Groups Range Wave Numbers 
1. N – H Stretching  3300-3500 cm-1 3290 cm-1 
2. C  C Stretching  2140-2100 cm-1 2108 cm-1 
3. C – N Stretching 1360-1080 cm-1 1334 cm-1 
 
STABILITY STUDIES 
The formulation F8 was selected for stability studies on the basis of their 
high cumulative percentage drug release and also results of less moisture 
absorption ratio. The stability studies carried out at 25˚C (room temperature) & 
40˚C/75˚ RH for the best formulations up to 30 days. In 15 day time interval, the 
chewing gums were analyzed for hardness, drug content uniformity, % drug 
release up to 30 days. The formulation showed not much variation in any 
parameter. The results shown in Figure 17.  From these results, it was concluded 
that formulation F8 (β-cyclodextrin) was stable and retained its original properties. 
The results obtained are tabulated in Table 12A. 
POST COMPRESSION EVALUATION STUDIES 
a. General appearance 
The formulated chewing gums were orange in color. All chewing gums 
were elegant in appearance Table. 8. 
b. Drug content of Lymecycline chewing gum 
The drug content of the best formulation as given (F8-βCD) in Table.6                      
which shows an uniform drug content in the formulation. 
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c. Thickness and Diameter 
The thickness for the best formulation was (F8-βCD). The result was 
summarized in Table and Figures 6. The diameter of the best formulation was 
(F8-βCD). The results indicated a uniform particle size distribution and no 
deformities. 
d. Hardness: 
The hardness for the best formulation was found to be (F8). The results 
indicated that the tablets of formulation have good hardness, which in turn 
protects from mechanical damage. The results were summarized in Table 6. 
e. Weight Variation: 
The average weight of the best formulation (F8) was found to be                     
1.010 ± 0.005 mg and tabulated in Table 6. The best formulation chewing gums 
passes weight variation test and the weight variation was within the 
pharmacopoeia limits of ± of the weight. The results indicated that all chewing 
gums of best formulation (F8-βCD) have uniform weight. 
f. Comparison of Invitro dissolution studies of Lymecycline chewing gum 
with Lymecycline pure drug: 
The dissolution study was carried out in pH 6.8. Invitro drug release profile 
of Lymecycline chewing gums (best formulation F8 – βCD) showed better 
dissolution rate (98.26%) when compared with marketed capsules [92.89%]. The 
results were shown in Figure. 16. 
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g. Anti-Microbial activity of Prepared Medicated Chewing Gum 
 The anti-microbial activity was carried out in organism streptococci & 
staphylococci and Amikacin was used as a standard drug. The results were 
shown in Table. 13. Figure. 20. 
TABLE: 1 CALIBRATION OF LYMECYCLINE BY USING 
PHOSPHATE BUFFER pH– 6.8 
 
S.NO. Concentration (µg/ml) Absorbance ± SD 
1. 5 0.1421 ± 0.010 
2. 10 0.2901±0.016 
3. 15 0.4289±0.022 
4. 20 0.5712±0.051 
5. 25 0.7003±0.048 
6. 30 0.8101±0.053 
 
    Regression Value = 0.99978 ± .001 
  
TABLE: 2 A TYPICAL GUM BASE FORMULA 
Ingredient Amount (%) 
Gum base 20-90% 
Softeners 5-35% 
Elastomers  10% 
Sweeteners 30-60% 
Texture agent/ filler 4-50% 
Colorants Up to 1% 
Flavoring agents 2-5% 
Humectants 10% 
Miscellaneous  
(Preservatives, Antioxidants) 
0.1% 
 
TABLE:3 COMPOSITION OF TYPICAL GUM BASE 
Components Function 
Elastomers and Poly vinyl acetate Chewable synthetic material 
Resins Plasticizing agent 
Waxes and fats Softening/emulsifying agent 
BHT Anti-oxidant 
 
  
TABLE: 4 FORMULATION OF MEDICATED CHEWING GUM BY MELTING METHOD (F1 TO F8) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Lymecycline 400 400 400 400 400 400 400 400 
Gum base 200 200 200 200 250 250 250 250 
Glycerol 10 15 20 25 10 15 20 25 
Sucrose 100 100 100 100 100 100 100 100 
Calcium Carbonate 35 35 35 35 35 35 35 35 
Liquid glucose 45 45 45 45 45 45 45 45 
Mannitol 202 197 192 187 152 147 142 137 
Aspartame 5 5 5 5 5 5 5 5 
Flavor 3 3 3 3 3 3 3 3 
 
Total weight of each chewing gum = 1000mg 
  
TABLE: 5 FORMULATION OF MEDICATED CHEWING GUM BY MELTING METHOD (F9 TO F16) 
Ingredients F9 F10 F11 F12 F13 F14 F15 F16 
Lymecycline 400 400 400 400 400 400 400 400 
Gum base 300  300 300 300 300 300 300 300 
Glycerol 10 15 20 25 10 15 20 25 
Sucrose 100 100 100 100 100 100 100 100 
Calcium Carbonate 35 35 35 35 35 35 35 35 
Liquid glucose 45 45 45 45 45 45 45 45 
Mannitol 102 97 92 87 52 47 42 37 
Aspartame 5 5 5 5 5 5 5 5 
Flavor 3 3 3 3 3 3 3 3 
 
Total weight of each chewing gum: 1000mg 
  
TABLE: 6  POST COMPRESSION STUDY FOR LYMECYCLINE 
MEDICATED CHEWING GUM FORMULATIONS 
 
Formulat
ion Code 
Weight 
uniformity 
test ± SD 
Drug 
content in 
percentage 
± SD 
Hardness  
(kg/cm2 ) 
Thickness 
(mm) 
± SD 
Friability ± 
SD 
F1 996.9±.1.33 90.82±0.63 2.2±0.2 4.0±0.06 0.74±0.07 
F2 997.5±0.08 93.33±0.62 2.3±0.11 4.0±0.10 0.63±0.04 
F3 996.9±0.75 95.58±0.76 2.3±0.15 3.9±0.01 0.65±0.01 
F4 996.7±0.44 94.49±0.89 2.4±0.20 3.7±0.03 0.61±0.01 
F5 997.2±0.18 92.87±0.21 2.4±0.15 3.8±0.03 0.62±0.04 
F6 996.6±0.79 96.62±0.28 2.2±0.06 3.8±0.03 0.65±0.04 
F7 997.1±1.30 94.93±0.67 2.1±0.06 3.8±0.02 0.82±0.01 
F8 996.7±0.19 98.03±0.65 2.0±0.06 3.9±0.03 0.89±0.01 
F9 996.3±0.22 95.01±1.11 2.0±0.10 3.9±0.02 0.74±0.02 
F10 996.6±0.17 94.61±0.24 1.9±0.10 3.6±0.04 0.84±0.02 
F11 996.8±0.49 95.10±0.12 1.9±0.06 3.6±0.04 0.54±0.02 
F12 996.6±0.21 93.67±0.77 2.5±0.23 3.5±0.02 0.57±0.03 
F13 997.1±0.10 94.45±0.12 2.5±0.06 4.0±0.01 0.56±0.03 
F14 996.9±0.41 93.50±0.60 2.5±0.06 4.0±0.07 0.58±0.04 
F15 997.5±0.12 94.84±0.04 2.4±0.06 4.0±0.06 0.63±0.04 
F16 996.5±0.59 94.50±0.21 2.3±0.06 4.0±0.02 0.68±0.15 
7 
  
TABLE: 7 RESULTS OF WEIGHT VARIATION (%/wt) 
No. FORMULATIONS WEIGHT VARIATIONS[g] 
1. F1 1.080±0.05 
2. F2 0.995±0.06 
3. F3                    1.012±0.06 
4. F4 1.086±0.06 
5. F5 1.290±0.05 
6. F6 0.981±0.01 
7. F7 1.016±0.03 
8. F8 1.010±0.05 
9. F9 1.003±0.01 
10. F10                    1.008±0.05 
11. F11 1.016±0.08 
12. F12 1.051±0.01 
13. F13 1.014±0.06 
14. F14 0.999±0.04 
15. F15 1.005±0.01 
16. F16 1.072±0.03 
TABLE: 8 EVALUATION PARAMETERS OF MEDICATED CHEWING GUMS 
S.NO. 
FORMULATION 
CODE 
COLOR 
TEXTURE FEEL 
(OR) 
APPEARANCE 
STICKINESS 
DRUG 
CONTENT (%) 
1. F1 Light Orange Good NIL 90.82±0.63 
2. F2 Light Orange Good NIL 93.33±0.62 
3. F3 Light Orange Hard NIL 95.58±0.76 
4. F4 Light Orange Good NIL 94.49±0.89 
5. F5 Light Orange Soft NIL 92.87±0.21 
6. F6 Light Orange Good NIL 96.62±0.28 
7. F7 Light Orange Good NIL 94.93±0.67 
8. F8 Light Orange Soft NIL 98.03±0.65 
9. F9 Light Orange Hard NIL 95.01±1.11 
10. F10 Light Orange Solid mass NIL 94.61±0.24 
11. F11 Light Orange Soft NIL 95.10±0.12 
12. F12 Light Orange Good NIL 93.67±0.77 
13. F13 Light Orange Good NIL 94.45±0.12 
14. F14 Light Orange Good NIL 93.50±0.60 
15. F15 Light Orange Soft NIL 94.84±0.04 
16. F16 Light Orange Soft NIL 94.50±0.21 
±
TABLE: 9 DETAILS OF DISSOLUTION STUDY 
DISSOLUTION TEST APPARATUS: 
1. Speed 50 strokes per min 
2. Volume of Medium 500 ml 
3. 
Sample withdrawal at each 
time interval 
2.8 ml 
4. Medium used Phosphate buffer (pH 6.8) 
5. Temperature 37 ± 0.5˚ C 
 
  
TABLE: 10A IN-VITRO RELEASE PROFILE OF MEDICATED CHEWING GUM LYMECYCLINE [F1-F8] 
FORMULATION 
CODE 
5TH  
MINUTE 
10TH MINUTE 15TH MINUTE 20TH MINUTE 25TH MINUTE 30TH MINUTE 
F1-PVA 47.7±0.82 55.5±1.05 62.67±0.81 69.90±1.04 75.43±0.84 85.13±0.69 
F2-PVA 42.61±0.58 49.77±0.88 53.35±0.65 61.54±1.33 76.44±1.10 82.69±1.02 
F3-PVA 42.83±0.70 58.35±0.65 66.95±2.53 71.93±2.86 75.06±1.22 79.79±0.83 
F4-PVA 43.43±0.71 51.28±0.77 60.40±0.69 64.36±1.06 70.13±0.57 75.43±1.05 
F5-BCD 55.43±1.03 63.13±0.91 70.77±1.43 75.44±1.13 84.34±1.57 90.28±0.99 
F6-BCD 55.32±1.43 63.21±0.91 71.09±0.49 79.84±1.48 88.52±1.29 92.89±1.31 
F7-BCD 55.54±0.87 64.89±2.15 73.05±1.26 73.45±0.23 89.27±0.23 94.26±0.56 
F8-BCD 47.23±0.77 54.03±2.23 64.11±0.98 73.88±0.45 84.29±1.72 98.26±0.78 
 
  
TABLE: 10B IN-VITRO RELEASE PROFILE OF MEDICATED CHEWING GUM LYMECYCLINE 
FORMULATION 
CODE 
5TH 
MINUTE 
10TH MINUTE 15TH MINUTE 20TH MINUTE 25TH MINUTE 30TH MINUTE 
F9-PEG 58.68±0.65 65.02±0.70 71.63±0.66 76.13±1.36 83.15±1.69 90.63±1.43 
F10-PEG 47.69±0.81 55.52±1.05 62.67±0.81 68.90±1.04 76.46±0.96 85.49±0.73 
F11-PEG 42.14±0.89 48.91±0.12 55.91±0.55 64.35±0.61 76.21±1.72 80.52±0.78 
F12-PEG 31.63±0.69 38.73±1.18 45.72±1.08 56.72±1.08 66.01±1.50 83.47±1.66 
F13-CP 45.22±1.91 56.46±1.67 67.51±0.45 76.36±0.24 81.93±0.76 91.76±0.56 
F14-CP 42.61±0.93 60.89±2.12 68.27±0.92 76.19±1.87 81.81±1.94 88.59±1.09 
F15-CP 50.43±0.55 63.68±0.86 69.10±0.96 74.59±1.06 79.75±0.39 85.39±0.39 
F16-CP 40.79±1.48 49.12±2.59 55.5±1.03 64.19±0.48 77±0.55 81.96±0.81 
 
  
TABLE: 11 IN-VITRO RELEASE KINETICS DATA OF LYMECYCLINE CHEWING GUM 
Formulation 
Code 
ZERO ORDER FIRST ORDER HIGUCHI 
KORSMEYER 
PEPPAS 
HIXSON 
CROWELL 
r2 K0(h-1) r2 K1(h-1) r2 KH(h-1/2) r2 n r2 KHC(h-1/3) 
F1 0.813 2.611 0.945 -0.034 0.970 16.39 0.968 1.491 0.853 -0.072 
F2 0.823 2.723 0.969 -0.044 0.975 17.03 0.956 1.491 0.922 -0.083 
F3 0.798 2.746 0.986 -0.048 0.969 17.39 0.988 1.520 0.939 -0.086 
F4 0.902 2.703 0.967 -0.034 0.992 16.29 0.968 1.304 0.929 -0.075 
F5 0.864 2.805 0.985 -0.041 0.990 17.26 0.974 1.383 0.952 -0.083 
F6 0.853 2.816 0.968 -0.084 0.983 17.38 0.957 1.436 0.918 -0.091 
F7 0.794 1.821 0.995 -0.010 0.967 11.55 0.991 1.351 0.994 -0.029 
F8 0.817 1.970 0.989 -0.012 0.973 12.36 0.973 1.350 0.965 -0.034 
F9 0.796 2.016 0.983 -0.013 0.964 12.76 0.976 1.401 0.970 -0.035 
F10 0.829 1.904 0.998 -0.012 0.981 11.91 0.995 1.301 0.998 -0.032 
F11 0.796 1.946 0.998 -0.012 0.966 12.33 0.983 1.381 0.991 -0.034 
F12 0.794 2.036 0.987 -0.013 0.964 12.89 0.975 1.412 0.982 -0.036 
F13 0.800 2.719 0.989 -0.043 0.971 17.22 0.992 1.509 0.951 -0.081 
F14 0.796 2.734 0.990 -0.045 0.968 17.34 0.983 1.516 0.955 -0.083 
F15 0.760 2.673 0.947 -0.053 0.950 17.17 0.980 1.584 0.858 -0.087 
F16 0.827 2.654 0.939 -0.039 0.969 16.51 0.925 1.481 0.890 -0.077 
  
TABLE: 12A STABILITY STUDIES OF BEST FORMULATION [F8] 
TEMPERATURE DAYS 
DRUG CONTENT 
(%) 
HARDNESS 
(kg/cm2) 
DRUG RELEASE 
(%) 
25˚C 
15 98.00 ± 0.13 2.63 98.2% 
30 97.8 ± 0.19 2.63 98.10% 
40˚C/75% RH 
15 97.9 ± 0.29 2.7 97.56% 
30 97.6 ± 0.26 2.7 97.18% 
 
  
 TABLE: 12B IN VITRO DRUG RELEASE OF STABILITY STUDIES FOR THE BEST FORMULATION (F8) 
TIME IN 
MINUTES 
CONTROL 
25˚C (ROOM TEMPERATURE) 40˚ / 75% RH 
15TH DAY 30TH DAY 15TH DAY 30TH DAY 
5 60.90±0.52               61.23±1.80 63.16±1.15 61.5±1.87 61.5±1.87 
10 69.74±2.26 69.90±1.80 72.37±1.86 68.67±2.13 69.30±2.32 
15 77.03±1.88 77±0.90 77.70±1.04 76.03±3.52 76.3±1.78 
20 85.52±2.26 83.17±2.27 83.60±2.05 82.90±3.83 83.97±0.58 
25 92.21±2.38 90.00±2.3 90.01±1.09 91.03±0.97 91.67±0.38 
30 98.60±0.91 98.2±0.66 98.07±0.67 97.5±0.57 97.17±0.49 
 
 TABLE: 13 ANTI – MICROBIAL ACTIVITY OF MEDICATED CHEWING GUM 
 
Sample Code 
(Lymecycline) 
Streptococci Staphylococci 
Lymecycline 15  mm 14 mm 
Standard drug (Amikacin) 20 mm 20 mm 
 
FIGURE: 1  DETERMINATION OF max OF LYMECYCLINE IN PHOSPHATE  
BUFFER pH 6.8 
 
 
 
 
FIGURE:2   CALIBRATION OF LYMECYCLINE BY USING PHOSPHATE  
BUFFER (PH 6.8) 
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FIGURE: 3A   FT-IR SPECTRUM OF LYMECYCLINE 
 
 
FIGURE: 3B   FT-IR SPECTRUM OF  POLY VINYL ALCOHOL 
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FIGURE: 3C   FT-IR SPECTRUM OF  BETA CYCLODEXTRIN 
 
 
FIGURE: 3D FT-IR SPECTRUM OF CROS POVIDONE 
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FIGURE: 3E   FT-IR SPECTRUM OF MANNITOL 
 
 
FIGURE:3F   FT-IR SPECTRUM OF CALCIUM CARBONATE 
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FIGURE: 3G   FT-IR SPECTRUM F LYMECYCLINE +PEG 4000 
 
 
FIGURE: 3H   FT-IR SPECTRUM F LYMECYCLINE + CROSPOVIDONE 
 
 
400600800100014001800240032004000
1/cm
0
5
10
15
20
25
%T
3
9
9
4
.5
8
3
9
7
5
.2
9
3
9
6
1
.7
9
3
9
3
4
.7
8
3
9
0
5
.8
5
3
8
7
3
.0
6
3
8
5
3
.7
7
3
8
4
2
.2
0
3
8
2
4
.8
4
3
7
8
6
.2
7
3
7
7
0
.8
4
3
7
2
4
.5
4
3
7
1
2
.9
7
3
6
9
1
.7
5
3
6
7
8
.2
5
3
4
0
2
.4
3
3
3
8
5
.0
7
3
2
6
5
.4
9
3
2
4
6
.2
0
3
1
9
0
.2
6
3
1
6
9
.0
4
3
1
5
3
.6
1
3
0
4
9
.4
6
3
0
2
4
.3
8
2
9
4
5
.3
0
2
8
8
5
.5
1
2
7
4
0
.8
5
2
6
9
4
.5
6
2
3
6
0
.8
7
2
3
4
3
.5
1
2
3
3
5
.8
0
2
2
3
7
.4
3
2
1
8
9
.2
1
2
1
6
6
.0
6
2
1
0
4
.3
4
2
0
8
5
.0
5
2
0
5
8
.0
5
2
0
3
2
.9
7
1
9
7
1
.2
5
1
8
9
9
.8
8
1
8
7
2
.8
8
1
8
4
9
.7
3
1
8
1
6
.9
4
1
7
1
8
.5
8
1
6
0
0
.9
2
1
5
8
1
.6
3
1
5
1
2
.1
9
1
4
6
7
.8
3
1
4
0
0
.3
2
1
3
5
7
.8
9
1
3
4
2
.4
6
1
2
8
0
.7
3
1
2
4
2
.1
6
1
1
4
7
.6
5
1
1
0
7
.1
4
1
0
6
0
.8
5
9
9
5
.2
7
9
6
2
.4
8
9
4
7
.0
5
8
4
2
.8
9
8
2
5
.5
3
8
1
0
.1
0
7
8
1
.1
7
7
4
2
.5
9
7
0
5
.9
5
6
7
3
.1
6
6
2
1
.0
8
5
8
6
.3
6
5
3
0
.4
2
5
0
9
.2
1
4
8
7
.9
9
4
6
0
.9
9
4
3
7
.8
4
4
2
6
.2
7 4
1
4
.7
0
lymecyclin + PEG 4000 1
400600800100014001800240032004000
1/cm
0
2
4
6
8
10
12
14
%T
3
9
9
4
.5
8
3
9
7
5
.2
9
3
9
6
1
.7
9
3
9
4
4
.4
3
3
9
0
7
.7
8
3
8
8
0
.7
8
3
8
5
3
.7
7
3
8
3
2
.5
6
3
7
7
2
.7
6
3
7
6
1
.1
9
3
4
0
2
.4
3
3
3
8
5
.0
7
3
3
2
5
.2
8
3
2
7
7
.0
6 3
0
8
9
.9
6
3
0
5
7
.1
7
2
9
5
3
.0
2
2
9
2
6
.0
1
2
8
9
5
.1
5
2
3
7
8
.2
3
2
3
3
5
.8
0
2
2
0
0
.7
8
2
1
8
5
.3
5
2
1
6
9
.9
2
2
1
3
9
.0
6
2
0
6
3
.8
3
2
0
3
4
.9
0
2
0
0
9
.8
3
1
9
8
2
.8
2
1
9
5
0
.0
3
1
9
2
6
.8
9
1
8
9
9
.8
8
1
8
7
2
.8
8
1
8
5
1
.6
6
1
7
8
6
.0
8
1
6
5
1
.0
7 1
5
0
0
.6
2
1
4
9
0
.9
7
1
4
5
0
.4
7
1
4
3
5
.0
4 1
3
8
1
.0
3
1
2
9
0
.3
8
1
2
3
0
.5
8 1
1
7
2
.7
2 1
1
4
7
.6
5
1
1
0
9
.0
7
1
0
6
2
.7
8
1
0
3
9
.6
3
1
0
1
8
.4
1
1
0
0
2
.9
8
9
4
8
.9
8
9
3
3
.5
5
8
9
4
.9
7
8
4
2
.8
9 8
2
3
.6
0
7
3
6
.8
1
6
4
6
.1
5
5
7
4
.7
9
5
4
3
.9
3
5
0
3
.4
2
4
8
6
.0
6
4
6
8
.7
0 4
3
7
.8
4
lymecyclin + crospovidone 
FIGURE:3I   FT-IR SPECTRUM F LYMECYCLINE +  B-CD 
 
 
FIGURE: 3J   FT-IR SPECTRUM F LYMECYCLINE + PVA 
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FIGURE: 4  WEIGHT UNIFORMITY OF LYMECYCLINE MEDICATED  
CHEWING GUM 
 
 
FIGURE: 5  DRUG CONTENT FOR LYMECYCLINE MEDICATED  
CHEWING GUM 
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FIGURE: 6  HARDNESS OF LYMECYCLINE MEDICATED  
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FIGURE: 7  THICKNESS OF LYMECYCLINE MEDICATED  
CHEWING GUM 
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FIGURE: 8  FRIABILITY FOR LYMECYCLINE MEDICATED  
CHEWING GUM 
 
 
 
 
 
 
 
 
 
 
 
 
  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16
F
ri
a
b
il
it
y
FOORMULATION CODE
FIGURE: 9A  INVITRO DRUG RELEASE OF LYMECYCLINE CHEWING GUM  
WITH PVA AT DIFFERENT CONCENTRATIONS 
 
FIGURE: 9B  INVITRO DRUG RELEASE OF LYMECYCLINE CHEWING GUM  
WITH -CD AT DIFFERENT CONCENTRATIONS 
 
FIGURE: 9C  INVITRO DRUG RELEASE OF LYMECYCLINE CHEWING GUM  
WITH PEG AT DIFFERENT CONCENTRATIONS 
 
FIGURE: 9D  INVITRO DRUG RELEASE OF LYMECYCLINE CHEWING GUM  
WITH CROS POVIDONE AT DIFFERENT CONCENTRATIONS 
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FIGURE: 10A COMPARISION OF INVITRO DRUG RELEASE PROFILE OF 
LYMECYCLINE MEDITATED CHEWING GUM CONTAINING 
PVA AT DIFFERENT RATIOS 
 
FIGURE: 10B COMPARISION OF INVITRO DRUG RELEASE PROFILE OF 
LYMECYCLINE MEDITATED CHEWING GUM CONTAINING   
-CD AT DIFFERENT RATIOS 
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FIGURE:  12D COMPARISION OF INVITRO KORES-MEYER KINETICS OF 
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FIGURE 16: INVITRO RELEASE PROFILE OF LYMECYCLINE PURE DRUG 
AND BEST FORMULATION (F8) 
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FIGURE 18:  DRUG CONTENT OF BEST FORMULATION (F8) 
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FIGURE: 20 ANTIBACTERIAL ACTIVITY OF LYMECYCLINE CHEWING GUM 
BY DISC DIFFUSION METHOD 
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CHAPTER-XI 
SUMMARY AND CONCLUSION 
 In the present study, an attempt has been made to formulate medicated 
chewing gum of lymecycline to achieve better patient compliance and 
improved drug release. 
 The results of compatibility studies by infrared spectroscopy and 
differential scanning colorimetric (DSC), showed no interaction between 
the drug and stabilizers. 
 Medicated chewing gum of Lymecycline were successfully prepared by 
melting method using different concentrations of polymers, PVA, BCD, 
PEG-4000, cros povidone and without polymers. 
 The presence of polymers made the chewing gum more stable with 
increasing drug release. 
 Plasticizer ratio and synthetic gum base concentration are critical 
parameters which affect the consistency and drug release profile. 
 The Drug content of the selected formulations (F8) was 98.03%, which 
indicates the maximum amount of drug present in the formulation chewing 
gum. 
 In Vitro release study of all the formulations were showed in increase drug 
release with increase in concentration of polymers (PVA, PEG-4000 ,β-
CD, Cros Povidone ) Dissolution rate of all the formulations were improved 
when compared to pure drug. 
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 The dissolution study was carried out in PH 6.8 phosphate buffer for 30 
minutes. The formulations shows rapid release of drug in 20 minutes & all 
formulations showed more than 90% of drug release. 
 Medicated chewing gum consisted mainly of calcium carbonate and gum 
base showed good elasticity, chew ability and satisfactory drug release. 
 The selected best formulation was tested for its antibacterial activity. 
 Chewing gum (Lymecycline) showed increased with Lymecycline 
capsules. 
 The faster onset of action desired in delivery of indicated chewing gum.  
 In all the formulations, F8 shows highest drug release of in 30 minutes. 
 The invitro release studies revealed that the prepared chewing gums 
showed a faster drug release when compared to the pure drug. 
 The formulations are kept for accelerated stability studies; they showed no 
change in the drug release profile. Thus stability results prove that the 
formulation was stable at accelerated conditions. 
 Conclusion: 
 Hence, it was concluded that Medicated chewing gum of lymecycline was 
successfully prepared by melting method using different concentrations of 
plasticizer and synthetic gum base, Formula is optimized by changing the 
plasticizer ratio and synthetic gum base concentration are critical 
parameters which effect the consistency and drug release profile. Based 
on the drug release files of all the formulations, formulation F8 is the 
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optimized formulations are kept for stability studies. Thus, it’s the better 
option to prepare Lymecycline into a medicated chewing gum to achieve 
better patient compliance and improved drug release. 
 From this study it was concluded that chewing gum that contains highest 
amount of β-cyclodextrin showed good release in invitro studies. It 
indicates that B-cyclodextrin acts as a good solubilizer which enhances the 
solubility of the drug Lymecycline. Higher polymer ration enhances drug 
solubility, which leads to increase in the amount of drug absorption. By 
delivering Lymecycline in the form of chewing gum, it directly enters into 
systemic circulation thus by passes first pas metabolism and hence bio 
availability of drug increase. 
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